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Monitoring for internal exposures to uranium and calculating the corresponding 
Committed Effective Dose (CED) can be complex.  Several contributing 
parameters such as the differences in the physiochemical nature of the uranium 
compound, the nature of the exposure scenario, variances in human metabolic 
behaviour and the capabilities of available bioassay techniques add uncertainty in 
developing an Internal Dosimetry and Monitoring Programme (IDMP).  Necsa’s 
IDMP was reviewed and found to be in line with best international practices and 
adequate for monitoring routine exposures to Type M uranium.  As found in 
literature and shown in the present study, the monitoring for Type S uranium is 
problematic.  The present study recommends continuance with the current Type S 
monitoring programme, however, the need for faecal analysis was identified.  A 
combination of bioassay techniques can assist in determining the unknowns in the 
abovementioned contributing parameters.  Analysis done to quantify the effect of 
differences in the contributing parameters has brought an understanding on how 
these parameters can influence and IDMP and knowledge gained from the present 
study will further enhance the programme and assist in developing the necessary 
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CHAPTER 1  
INTRODUCTION 
 
A facility that handles uranium in significant quantities requires a programme to 
monitor internal contamination and to quantify the effect of the internal 
exposures.  
 
Regulatory requirements compel such a facility to ensure exposures to workers 
and the public are justified, optimised and limited.  A programme of monitoring 
the environment and workers is required to demonstrate that exposures are 
optimised and below regulatory limits.  An Internal Dosimetry and Monitoring 
Programme (IDMP) forms part of the abovementioned requirements.  The 
primary objective of an IDMP is the calculation of committed effective doses 
from intakes of radioactive material encountered in the workplace.  Such an 
IDMP has to be technically justified and should comply with international best 
practices. 
 
Raabe [RA94] defines Internal Dosimetry (ID) as “...the scientific methodology 
used to measure, calculate, estimate, assay, predict, and otherwise quantify the 
radioactive energy absorbed by the ionization and excitation of atoms in human 
tissues as a result of the emission of energetic radiation by internally deposited 
radionuclides”.  The National Radiological Protection Board of the United 
Kingdom [NR04] defines a Monitoring Programme (MP) as “…a combination of 
the monitoring strategy (task, routine, special), the location of the monitoring 







A very basic structure of an IDMP is as follows:  
 
Step 1 Worker internally exposed to radionuclides (e.g. uranium). 
 
Step 2 Determine uptake amount of radionuclides in the body by means of an 
appropriate individual monitoring method (e.g. bioassay) and/or 
workplace monitoring programme (e.g. airborne contamination). 
 
Step 3 Calculate Committed Effective Dose (CED) from the uptake using 
biokinetic models published by the International Commission on 
Radiation Protection (ICRP). 
 
An IDMP forms an integral component of ensuring radiation safety within a 
facility.  Workers at the South African Nuclear Energy Corporation (Necsa) who 
handle nuclear materials such as uranium are potentially at risk of inadvertent 
intakes of radioactive material.  The most significant intakes of radionuclides 
usually occur when there is an accidental release of radioactive material in the 
workplace or when there is a loss of containment.  Workplace and individual 
monitoring programmes are designed to provide the data needed (uptakes) to 
assess organ and tissue dose equivalents as well as determining the CED.   
 
1.1 Statement of the problem 
Uranium intake resulting in internal contamination represents an occupational risk 
to workers involved in the uranium industry.  A monitoring programme capable of 
detecting internal exposures should be planned and implemented whenever an 
employee is potentially exposed to intakes of uranium.  The objective of 
monitoring is to verify that workers are adequately protected against risks arising 
from intakes and to document this monitoring.  Prompt and accurate assessment 
of internal exposures is important in determining each individual’s CED and in 
establishing an accurate historical record. 
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Necsa’s workforce is exposed to a wide spectrum of possible internal intakes from 
various uranium compounds, thus requiring a comprehensive IDMP.  Recently, a 
state of the art Whole Body and Lung Counter (WBLC) was purchased.  This has 
significantly improved the measuring methods that are now available and also 
resulted in an enhanced sensitivity for lung counting.  Dose calculating software, 
known as Integrated Modules for Bioassay Analysis (IMBA), was also purchased 
which has improved the accuracy (best estimate) of reported results.  Calculating 
doses is also less cumbersome with the new software.  Current documentation at 
Necsa lacks a holistic overview of an IDMP.  Necsa’s policy and guiding 
principles on monitoring are clearly stated but the technical justification for dose 
calculations methodologies and monitoring programmes are not clearly 
documented.   
 
Internationally, there have been significant developments regarding IDMP in 
recent years.  However interlaboratory comparisons have revealed that different 
laboratories can obtain quite different estimates of intakes and doses when 
provided with the same monitoring data [DO07].  This was due to several reasons 
such as level of expertise of participants, errors in transcripts, assumptions made 
about time of intake and biokinetic models.  Rahola [RA03] pointed out the lack 
of common strategies for monitoring programmes and found differences in routine 
monitoring for uranium.  In terms of mitigation, a lot of effort has gone into the 
many studies needed to harmonise and optimise internal dosimetry practices, 
especially in the European Union (EU).  The need for harmonisation of 
assessment procedures and monitoring protocols has been recognised in a research 
project carried out under the EU 5th Framework Programme.  This has also 
prompted the International Standards Organisation (ISO) and European Radiation 
Dosimetry Group (EURADOS) to publish guidance documents such as [ID06] 
and [NR04], the Internal Dose Equivalent Assessment System (IDEAS) and 
Optimisation of Monitoring for Internal Exposure (OMINEX), respectively.  
 
Taking into consideration recent international development as well as new 
equipment and software purchased and shortcomings in Necsa’s documentation, a 
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need has thus been identified to evaluate and optimise Necsa’s monitoring 
programme and to evaluate the dose calculating methods in order to ensure it is in 
line with and harmonised with international best practices.   
 
1.1.1 Importance of the problem 
The current scale of handling uranium and its compounds in fuel fabrication 
together with the possibility of future increases in volume indicates the 
importance of ensuring effective occupational monitoring of personnel.  The 
South African government has indicated in the Integrated Resource Plan for 
Energy [IR11] that it plans to increase the nuclear component of its energy mix. 
Monitoring programmes and dose calculation methodologies which are not 
properly developed and in line with best international practices could lead to 
unreliable CED assessments and to the possibility of not detecting intakes of 
radionuclides.  Personal monitoring provides an indication of the effectiveness of 
physical design features and administrative controls in controlling exposure to 
radioactive material and is an integral part of demonstrating compliance to 
regulatory requirements. 
 
1.2 Study objectives 
It is the primary objective of the present study to ensure that Necsa’s IDMP for 
uranium at a recovery and purification plant complies with national and 
international standards, legislation and best practices.  The IDMP should be 
adequate to demonstrate compliance with the performance criteria for monitoring 
and dose calculation.   
 
Information and knowledge should be obtained in order to: 
• assist in the design of monitoring programmes for individuals, 
• provide guidance on the interpretation of monitoring data and doses,  
• provide guidance on the estimation of associated doses and 
• assist in the development of technical basis documentation. 
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The results of the present study should contribute to the health and radiological 
protection of workers by improving the methods for assessing internal dose from 
measurements and by implementing a common, harmonised approach to the 
design and implementation of internal dose monitoring programmes.  The 
monitoring programme should be the best measurement, reflecting actual 
exposures.  This will result in more reliable estimate of doses.   
 
1.3 Limitation and scope of study 
The scope of the present study is to review international practices and 
methodologies in IDMP and to compare with Necsa’s programme.  A knowledge 
base will be built up containing best practices and these best practices will be 
presented in the study.  The present study will not include detailed descriptions of 
the biokinetic models, bioassay protocols and dose calculation methodologies.  It 
will rather focus on the development of guidelines to optimise internal dosimetry 
calculations and monitoring programmes and to ensure Necsa’s IDMP is in line 
with best international practices.  Also included will be recommendations on 
changes needed in Necsa’s IDMP.   
 
The project entails studying and understanding exposure scenarios within a 
uranium plant, and specifically the physiochemical nature of the uranium 
compounds found in a uranium plant.  A uranium monitoring programme, i.e. 
monitoring techniques and its capabilities, as recommend in literature will be 
described.  Necsa’s programme will be explained, its shortcomings highlighted 
and compared against cases found in the literature.  This includes a focus on 
important parameters used during dose calculations and the effect it has on the 
calculated CED.  Specifically, the study will include calculations and validation of 
limits of detection and performance criteria of monitoring techniques.   
 
The study will be limited to only uranium intake within the context of a uranium 
recovery and purification plant, explicitly the chemical processing and recovery, 
thus excluding e.g. fuel plate manufacturing.  Whenever the term uranium plant is 
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used, it refers to the chemical processing, recovery and purification of uranium 
and the manufacturing of uranium alloy metal. 
 
The chemical hazards of uranium intake will not be considered and the present 
study will only identify the internal radiological hazard of uranium.  External 
exposures from uranium will thus not be studied.  Elevated radon concentrations 
can occur in poorly ventilated uranium storage areas and the internal radiological 
hazards of radon and its short lived products are excluded in this study.  The study 
excludes criteria and conditions under which workers are to be included in a 
bioassay programme.  This study will be broadly based on a literature study and 
does not include actual experiments to determine the physiochemical nature of 
exposures.   
 
It is limited to routine monitoring of individuals exposed to Type M (medium 
solubility class) uranium.  Monitoring for exposures to Type S (slow solubility 
class) uranium, task related and special monitoring (including additional 
monitoring after an action level has been exceeded) is excluded.  The exclusions 
will be discussed, but not addresses specifically.  The focus will be on individual 
monitoring, and workplace monitoring programmes will be excluded.  Thus, it 
will not investigate the characteristics of workplace monitoring programmes (e.g. 
placement of workplace monitors etc.) in order to determine intakes.   
 
1.4 Report structure and study design 
The objective is to study available literature and provide a summary of the 
literature.  Literature from published journals will be reviewed, including reports 
from international organisations (IAEA, ICRP etc), and reports from open 
literature such as presentations at conferences and reports from institutions 
available on the internet.  
 
The three main chapters are: 
Chapter 2 – Theoretical considerations this chapter provides the scientific basis 
for the study.  It presents an overview and an understanding of an IDMP and its 
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requirements.  In particular it addresses the radiological decay characteristics of 
uranium and the biokinetic behaviour of uranium.  Knowledge gained in this 
chapter will be applied specifically to an uranium IDMP. 
 
Chapter 3 – Development of a uranium monitoring programme: results, 
discussion and recommendations in order to apply the requirements of an 
IDMP, one needs to investigate and analyse the specific characteristics of an 
uranium IDMP.  This entails first a detailed literature study on uranium’s 
physiochemical and radiological (particularly enrichment) properties as it is 
applicable specifically in the environment of an uranium plant and an estimate of 
the uncertainties associated with these properties.  The effect of these 
uncertainties is quantified.  Further, literature research is also done on exposure 
scenarios and the associated uncertainties.  Again specifically in the context of an 
uranium plant.  The effect of altering physiochemical and biokinetic parameters 
are thus quantified.  This will provide an understanding of the influence of these 
parameters and how it should be used in calculating doses.  Recommendations are 
made on addressing these unknowns.   
 
The second part of Chapter 3 investigates bioassay techniques and the various 
advantages and disadvantages of each technique.  An uranium monitoring 
programme, i.e. monitoring techniques and its capabilities, as recommended in 
literature will be described.  Necsa’s programme will be explained, its 
shortcoming highlighted and compared against literature.  Recommendations for 
improvements will be made.  Recommendations from Chapter 3 will improve 
Necsa’ capability to monitor for uranium and will also ensures calculated doses 




CHAPTER 2  
THEORY 
 
The purpose of this chapter is to provide a basic scientific overview of the theory 
and principles of an internal dosimetry and monitoring programme.  The physics 
and biology of radiation protection and the principles of dosimetry are discussed 
first (Section 2.1).  This includes the radiological characteristics of uranium and 
the ICRP biokinetics models.  Workplace characterisation (Section 2.2), which is 
used as a basis for a monitoring programme, is reviewed thereafter.  This entails 
the physiochemical nature of the intake compound and the characteristics of an 
exposure scenario.  The monitoring programme (Section2.3) and its 
characteristics, which ensures exposures are adequately monitored, is reviewed.  
The principles of internal dose calculation (Section 2.4) in order to ensure doses 
are the best estimate, is discussed.  This information will be applied in developing 
an IDPM specifically tailored for the situation at Necsa’s Uranium Plant.   
 
2.1 The physics and biology of radiation protection and 
dosimetry 
In order to practice radiation protection, one needs an understanding of both the 
physics and the biology of radiation protection.  The interaction between these 
two disciplines forms the basis for radiation protection principles.  
 
2.1.1 Radiological characteristics 
The radiological features of a material can be described by various physical 




Radioactivity is the process through which nuclei spontaneously emit subatomic 
particles.  The unit of activity is called the becquerel (Bq) and is defined as the 
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quantity of radioactive material in which one atom is transformed per second.  
Alternatively, it is defined as the number of disintegrations per atom per second.  
It should be noted that it is not the number of particles emitted per second, e.g. 
60Co emits 3 particles (one β--particle and two γ-rays per transformation).  
 
2.1.1.2 Half-life 
Half-life is defined as the time required for the activity of the sample to reduce by 







Material is also cleared from the human body at a specific rate, which is 
characterised by the biological half-life of the specific nuclide.  The biological 
half-life is analogous to a physical (radioactive) half-life and can also be described 
by Eq. (2.1).  The effective half-life (Te) is a combination of the physical (Tp) and 





 . (2.2) 
 
For radionuclides that decay into stable progeny, or into progeny with radioactive 
half-lives very much longer than the human lifespan, only the radiation emitted by 
the parent radionuclide need to be considered for dosimetry.  However, many 
radionuclides decay into short-lived progeny, or into progeny with an intermediate 
half-life.  For these radionuclides, the amount of in-growth of activity of the 
progeny must be taken into account (over the period for which the dose is to be 
integrated).  It should be noted that for calculation purposes the Integrated 
Modules for Bioassay Analysis (IMBA) software has various mathematical 
solutions to take this into consideration [BI94].   
 
Half-lives need to be considered when deciding on monitoring periods.  This is 
the case for radionuclides with a physical and or effective half-life within the 
same order as the monitoring period.  This is discussed further in Section 2.3.3.  
 10 
 
2.1.1.3 Types of radioactive decay 
When nuclei emit subatomic particles, their configuration, state, and even identity 
may change.  Typical decay mechanisms are shown below: 
 




—decay:  XZA  → Y + β- + veZ+1A  
electron capture:  X + e-ZA  → Y +  veZ-1A  
β
+
-decay:  X ZA → Y + β++veZ-1A  
gamma decay:  YZA  → Y + ZA γ   , 
 
where XZA  represents the initial nuclear species X with Z the atomic number 
(number of protons) and A the mass number (total protons and neutrons).  Here, Y 
represents the final nuclear species after decay.  There are two kinds of beta decay 
viz. β--decay (electron) and β+-decay (positron).  A positron has all the properties 
of an electron, but has a positive charge.  Electron capture occurs when a nucleus 
captures one of the orbital electrons and is competing with β+-decay.  During 
electron capture a proton is transformed into a neutron: 
p + e-→ n + ve  (2.3) 
which is also the case for β+-decay: 




However, for Β--decay a neutron is changed into a proton: 
n → p + β- + ve  . (2.5) 
 
In the above equations ve represent an electron neutrino and ve  represents an anti-
electron neutrino.  It should be noted that following β--decay or electron capture 
the daughter nucleus may be left in an excited state and which subsequently de-
excites by emitting a γ-ray(s).  In addition, electron capture leaves the daughter 
nucleus with a hole in the K or L electron shell orbits and a characteristics X-ray 
is produced when the hole is filled by a higher lying electron.  
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2.1.2 Radiological characteristics of uranium 
Uranium is a radioactive element that occurs naturally in varying but small 
amounts in soil, rocks, water and plants.  It has an atomic number of Z = 92 
(number of protons).  In nature, uranium exists as several isotopes viz. 238U, 235U 
and 234U being the most prevalent.  For naturally occurring uranium the 
abundance, half-life and specific activity (SA) is given in Table 2.1. 
 









234U 0.0055% 2.45 x 105 2.31 x 108 
235U 0.72% 7.04 x 108 8.00 x 104 
238U 99.27% 4.47 x 109 1.24 x 104 
 
All three naturally occurring isotopes are radioactive, emitting alpha particles and 
γ-rays.  The 235U isotope is capable of fission leading to the release of 
considerable energy.  It should be noted that 238U and 234U are part of the uranium 
decay series and 235U is part of the actinium decay series.  Here, 238U is the parent 
nucleus of the uranium decay series ending in the stable nuclide 206Pb.  In 
addition, 234U is a daughter of 238U and is found in nature in radioactive 
equilibrium (secular equilibrium) with its mother nucleus.  The daughter product 
radon (222Rn) is an inert gas and can easily migrate away from the source and is 
rarely found in equilibrium.  Also of note is that 234U does not emit any significant 
number of γ-rays.  Indeed, all the γ-rays emitted are with very low energies and 
with very low abundance.  The uranium series decay primarily by emission of 
alpha and β- particles (see Table 2.2).   
 
The actinium decay series (see Table 2.3) starts with the parent nucleus 235U and 
ends with stable 207Pb.  It also decays primarily by alpha and β- particles.  Of note 
is the 186 keV photon emitted by 235U, which is used in the detection of uranium.  
The 238U isotope does not emit any γ-rays, but the immediate daughter, 234Th, does 
emit a 93 keV and a 63 keV γ-ray, but with very low abundance (< 5%).   
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2.1.3 Interaction with matter 
Radiation carries energy and whenever it interacts with a medium it may deposit 
some or all of it to the atoms in the medium.  The result is some form of excitation 
or ionisation.  Excitation occurs when an electron is raised to a higher-lying orbit 
(higher energy state) within the absorbing atom.  Ionisation happens when the 
energy transferred exceeds the binding energy and the orbital electron is 
completely removed from the absorbing atom.  This excitation or ionisation can 
form a basis of signal formation for a detector and can be measured by the 
processing electronics. 
 
2.1.3.1 Interaction of particles 
Heavy particles, such as alpha particles, interact with matter through Coulomb 
forces between the positive charge of the alpha particles and the negative charge 
of orbital electrons within the absorbing atom.  The alpha particle interacts with 
several of the electrons and, depending on the proximity of the alpha particle, the 
electrons may either be ionised or excited.  These interactions decrease the energy 
(velocity) of the alpha particle, resulting in a specific range (depth of penetration) 
depending on the absorber material.   
 
Energy is converted into electromagnetic radiation (photons) during the 
interaction of energetic (fast) electrons with matter.  The fraction of electron’s 
energy converted increases with electron energy and is also dependent on the 
atomic number of the absorbing material.  The spectrum of photons produced is 
continuous and is called Bremsstrahlung radiation.  Backscatter occurs when low-
energy incident electrons undergoes large-angle deflection along their tracks.  Not 
all of the backscattered electron’s energy is deposited in the absorbing matter.   
 
A positron is emitted during β+-decay and its range is relatively short and at the 
end of the range, when the energy is low it combines with an electron.  The 
positron and the electron disappear and are replaced by two oppositely directed 
photons (due to conservation of momentum), each with an energy of 0.511 MeV 
 (the mass-energy equivalent of the electron)
annihilation.   
 
2.1.3.2 Interaction of photons
Photons can primarily interact with material in three different ways: 
absorption, compton scattering
the partial or complete transfer of photon energy to electron energy
 
During the photoelectric effect, all of the energy of the photon is absorbed and 
transferred to an orbital electron.  The atom is ionised (electron vacancy) when the 
electron is removed from the atom.  The kinetic energy of the removed electron is 
equal to the original energy of the photon minus the binding energy.  The vacancy 
is quickly filled by either a free electron or electron from a higher orbital shell 
resulting in the release of a characteristic X
absorption interaction.  
 
Figure 2.1: Photoelectric absorption
 
Compton scattering occurs when the incident photon interacts with an outer 
orbital electron, resulting in the ejection of the electron and scattering of the lower 
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.  This process is known as 
 
 and pair production.  All of these processes lead to 
-ray.  Fig. 2.1 depicts the 
 
 (taken from [AH07]). 
photoelectric 
 [AH07].  
photoelectric 
 
 energy photon.  The kinetic energy of the ejected electron (recoil electron) is 
dependent on the energy of the incident photon and the angle of the photon 
scattering.  The energy of the electron increases as the angle of the deflection 
increases and the scattered photon may continue with more compton interactions 
or photoelectric absorption.  The 
excitation or ionisation.  
 
Figure 2.2: Compton scattering
 
Pair production may occur 
should be more than twice the rest
electron-positron pair is created in
converted under the influences of the Coulomb field of a nucleus.  The excess 
energy (above 1.02 MeV) is shared as kinetic energy between the electron and 
positron.  When the positron slows down it will intera
in annihilation and the emission of two 0.51 MeV photons.  
 
The relative importance of the above three interactions 
Fig. 2.3.  It is depicted as a
the energy of the incident
depends on the energy of the incident p
occurs.  The line at the left represent the energy and 
the photoelectric absorption and the compton scattering are equally probable.  The 
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ejected electron deposits its energy through 
Fig. 2.2 depicts compton scattering. 
 (taken from [AH07]). 
with high energy photons.  The energy of the photon 
-mass energy (>1.02 MeV) of an electron.  
stantaneously when the energy of the photon is 
ct with an electron, resulting 
 
is graphically depicted in
 function of the Z number of the absorbing medium and 
 photon. The probability of a specific interaction 
hoton and medium in which the absorption 





line on the right represents where pair production and Compton scattering are 
equally probably.  Thus, three distinct areas are defined where each of the three 
interactions are prominent.  
 
 
Figure 2.3: Probability of the three main interactions of photons with matter 
(taken from [KN99]). 
 
2.1.4 Dosimetry quantities 
Radiation measurements and the investigation of radiation effects require various 
specifications of the radiation field at the point of interest. Radiation dosimetry is 
the quantitative determination of energy deposited in a given medium by directly 
or indirectly ionizing radiations. Various quantities and units have been defined 
for describing the interaction of radiation with tissue, and the most commonly 
used dosimetric quantities and their units are defined below. 
 
2.1.4.1 Fundamental quantities 
Kerma (K) is defined as the sum of the initial kinetic energies of all the charged 
particles liberated by uncharged ionizing radiation (i.e., indirectly ionizing 
radiation such as photons and neutrons) when travelling through a tissue of mass 
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dm [ST08].  Not all of the kinetic energy is absorbed through the processes 
described in Section 2.1.3 only some of the energy is lost.  As such, kerma is 
different from absorbed dose, according to the energies involved. At low energies 
it is almost equal, however, kerma is much larger than absorbed dose at higher 
energies since some of the energy escapes from the absorbing volume in the form 
of bremsstrahlung or fast moving electrons.  The main parameter of interest is 
absorbed dose, which is measured as energy deposited per unit mass.  Kerma (K) 
and absorbed dose (D) are given in Eq. (2.6) and (2.7). 
 
K = dETrdm  (2.6) 
D = dɛ̅dm (2.7) 
 
where dɛ̅ is the mean energy absorbed by matter of mass dm and dETr is the sum 
of the initial kinetic energy per unit mass dm.  The unit of absorbed dose is the 
gray (Gy), where 1 Gy = 1 J/kg.  
 
2.1.4.2 Linear Energy Transfer 
The biological damage created by ionising radiation relates to chemical alteration 
of the biological molecule caused by ionisation and excitation.  This is dependent 
on the local rate of energy loss along the particle’s track.  There are differences in 
the energy deposited per unit path length for the various types of ionising 
radiation.  For example, an alpha particle has a relatively short range in tissue and 
will thus have a high ionising intensity (energy deposited per unit length).  This 
characteristic is described by the Linear Energy Transfer (LET) of the various 
types of ionising radiation, as seen in the Table 2.4 [RA94].   
 
The LET is defined as the average instantaneous rate of energy loss to ionisations 
and excitations per unit path length.  As can be seen the LET’s of nuclear particles 
are significantly higher than those of electromagnetic radiation and 
electrons/positrons and tends to result in greater biological damage.  This is of 
specific interest in the present study where the main nuclide of interest is uranium 
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which decays predominantly by an alpha emission.  Alpha particles are easily 
absorbed by the dead layer of skin (external exposure) and are subsequently 
mainly a hazard with internal exposures where it deposits its energy over a very 
short range.  The internal doses received from uranium’s daughter build-up in the 
body is small (< 10%) compared with the doses received from the alpha decay of 
uranium.  This is because the short-lived daughters are emitting mostly beta and 
gamma (photon) radiation which has significantly lower LET values.   
 
Table 2.4: LET for different types of ionising radiation (taken from [RA94]). 
Type of Radiation 
LET 
(keV/µm) 
X-rays, γ-rays, β particles, electrons 0.2 – 2 
protons 15 – 25 
neutrons 20 – 80 
alpha particles 60 - 200 
 
2.1.4.3 Effective dose 
To express the relative effectiveness of different radiation, the absorbed dose (D) 
is multiplied by a radiation weighting factor, wR.  The weighing factor is summed 
if there are several types of radiation.  To take into consideration the difference in 
sensitivity of the various tissues and organs in the human body, the absorbed dose 
is also multiplied by a tissue weighing factor wT, which is also summed to take 
into account all the different tissues and organs.  The resulting effective dose (E) 
has the unit sievert (Sv) and is defined as: 
 







The radiation protection dose quantity, effective dose (E), is related to the human 
body and is not measurable.  For external dosimetry the operational dose quantity 
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is the personal dose equivalent (Hp10).  For internal dosimetry the operational dose 
quantity is the Committed Effective Dose (CED), E50.  The internal exposure is 
assessed over a period of 50 years.   
 
2.1.5 Detection equipment 
A detector responds to various types of radiation due to the interactions as 
described in Sections 2.1.3.  Energy from the interactions is converted into an 
electrical charge within the detector’s active volume.  The electrical charge is 
collected to form the basis for an electrical signal.  Typical detectors include: 
 
• ionisation chambers, 
• proportional counters, 
• Geiger-Müller counters and 
• scintillation counters. 
The characteristics of each of them are dealt with in turn below. 
 
2.1.5.1 Ionisation chambers 
Ionization chambers, like proportional counters and Geiger-Müller counters, are 
gas filled detectors.  An ionisation detector can operate with different gases and 
gas pressures but often air is used at atmospheric pressure and temperature. The 
gas absorbs the radiation’s energy which ionises and excites the gas atoms along 
the interacting particle’s track.  The number of ion pairs created (and collected) is 
proportional to the energy deposited by the ionising radiation in the gas volume 
during interactions. Alpha particles produces more ion pairs than β- particles and 
thus the chamber makes it possible to distinguish between the types of radiation 
with the pulse size being independent on the applied voltage.  This enables 
ionisation detectors to distinguish between different types of radiation viz. alphas, 
betas and gammas.  The ions move under the influence of the potential difference 
applied across the sensitive volume and are collected by the electrodes to form an 
electrical current which forms the basis of the measured electrical signal.  A 
typical ionisation chamber detector system is schematically shown in Fig. 2.4 with 
the essential components indicated as: 
 A gas filled container
E physically separated e
cathode) with 
P power supply 
D display. 
 
Figure 2.4: Typical i
 
2.1.5.2 Gas multiplication and p
Proportional counters typically contain a mixture of inert and organic gas
Counters filled with boron trifluoride (BF
proportional counter’
the detectors may operate at elevated gas pressures
provides higher detection
Sensitivity to low dose rates 
higher voltage accelerate
turn cause further ion




lectrodes (E1 - positive anode; 
a fixed potential difference (voltage) between electrodes
(battery) 
onisation chamber (taken from [IA04a]). 
roportional counters 
3) enable the detection of neutrons.
s electrical signal is based on the generation of pulses and 
.  The elevated gas pressure 
 efficiencies for X-rays, γ-rays and 
is increased due to the higher applied voltage.  
s the ions produced and the fast moving negative ions
ization (see Fig. 2.5).  This process is known as 
ication also occurs in Geiger-Müller counters









.   
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Figure 2.5: The effect of gas amplification in proportional counters (taken from 
[IA04a]). 
 
The number of ions collected by the electrode will be proportional to the number 
of ions produced by the radiation (similar to ionisation detectors).  A pulse of 
charge is generated when the ions are collected on the electrode and the 
subsequent pulse is proportional to the energy absorbed by the detector which thus 
still allows it the ability to distinguish between different types of radiation.  In the 
case of proportional counters, the pulse height is larger (improved sensitivity), in 
comparison with ionisation chambers, due to the increased voltage.  The pulse 
height is also proportional to the voltage across the electrodes. 
 
2.1.5.3 Detector regions and Geiger-Müller counters 
Geiger-Müller (GM) counters contain a low-pressure inert gas and traces of an 
organic or halogen gas called the quenching agent.  The potential difference 
between a GM’s electrodes is higher than proportional counters and large enough 
to cause a complete ionization of the detector gas.  This complete ionisation from 
the gas amplification is caused by a single primary ionization.  The size of the 
pulse is thus independent of the type of radiation.  A GM’s output differs from 
that of other gas filled detectors in that the pulses of electrical charge occurs at a 
count rate which is related to the radiation fluence (intensity). 
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The relative response of gas filled detectors to a single ionising particle is 
illustrated in Fig. 2.6.  The number of ions collected, n, per ionising particle is 
plotted against the detector voltage, V.  The difference between radiations types is 
also shown with the upper curve representing an alpha particle (more ion pairs 
created) and the lower curve a β- particle (less ion pairs created).  The different 
detector regions indicated are for 
 
A ionization chambers:  the range of voltage is above a minimum to prevent 
the recombination of ion pairs but large enough to collect the ions at the 
electrodes.  The voltage is also low enough to prevent gas multiplication. 
B proportional counters:  the region starts where secondary ionisation is 
being produced.  The detector’s response (sensitivity) increases with 
increasing ionisation due to the secondary ionisation. 
C Geiger-Müller counters:  an avalanche of ions is produced and collected.  




Figure 2.6: Typical output from gas filled detectors (taken from [IA04a]). 
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2.1.5.4 Scintillator counters 
The kinetic energy of an ionising particle is changed into a light photon during the 
fluorescence process.  Fluorescence is the prompt emission of visible light from a 
substance following its excitation.  This process occurs in a scintillation crystal.  
Such scintillation phenomena form the basis of a sensitive radiation detection 
system.  The scintillator crystal consists of a transparent crystal, usually a 
phosphor, plastic, or organic liquid that fluoresces when struck by ionizing 
radiation.  A sensitive photomultiplier tube (PMT) measures the ultra violet light 
from the crystal.  The PMT is attached to an electronic amplifier and other 
electronic equipment to count and quantify the amplitude of the signals produced 
by the PMT.  When a charged particle strikes the phosphor, a light photon is 
emitted.  This photon strikes the photocathode in the scintillator, releasing an 
electron.  This electron accelerates towards the first dynode, causing multiple 
secondary electrons to be emitted, which accelerate towards the second dynode.  
More electrons are emitted and the chain continues, multiplying the effect of the 
first charged particle.  This process is called photo-multiplication.  At the last 
dynode, a voltage pulse appears across the external resistors.  This voltage pulse is 
amplified and recorded.  The intensity of the light produced is directly 
proportional to the energy of the ionising particle and subsequently it can be used 
as a spectrometer with the appropriate electronics.  This process and the different 
components of a scintillator detector are depicted in Fig. 2.7. 
 
 




The sensitivity of bioassay techniques is dependent on the sensitivity of the 
instrument used.  Sensitivity is a measurement of the detection capability (level of 
activity measurable) of the technique and thus is an indication of the adequacy of 
a bioassay technique.  It should be noted that in statistics, the probability of a false 
positive and a false negative error is designated respectively by an alpha and beta 
probability and should not be confused with alpha- and β-particles.   
 
2.1.6.1 Decision level (LC) 
The decision level provides a way of distinguishing the difference between the 
result from an analyte and the result from an appropriate blank.  It answers the 
question whether a positive result has been detected with an alpha probability of 
Type I (false positive) and is calculated in Refs. [AN96] and [CU68] as: 
 
LC = 2.33σB , (2.9) 
 
where 
σB = standard deviation of net count of a subject with no added analyte 
(standard deviation of background sample) 
Type I = error set at 5%. 
 
2.1.6.2 Minimum detectable activity or detection limit 
The detection capability of a technique is characterised by its Minimum 
Detectable Activity (MDA) and is defined using an appropriate blank phantom or 
sample.  The MDA is also known as the detection limit or Lower Limit of 
Detection (LLD).  MDA is defined in Refs. [AN96] and [KR05] as the smallest 
amount (activity or mass) of an analyte in a sample that will be detected with a 
probability beta of non detection (Type II error) while accepting a probability 
alpha of erroneously deciding that a positive (non-zero) quantity of analyte is 




MDA =  2.71 + 2 LC , (2.10) 
MDA =  2.71 + 4.65σB ,  
 
where 
σB = standard deviation of net count of a subject with no added analyte 
(standard deviation of background sample) 
Type I, II = error for both set at 5%. 
 
2.1.7 ICRP biokinetic models 
The particle size being inhaled by a person and the person’s breathing pattern 
(mouth or nasal breather, heavy or normal breather) will determine how and 
where particles are deposited on the respiratory system [DO08].  The size of the 
aerosol particles will determine the region of the respiratory tract where most of 
them will be deposited.  These processes are described by the deposition model in 
ICRP 66 [IC94].  Mechanical and absorption processes determine the rate of 
clearance from the lungs.  Particles are cleared from the respiratory system 
through three clearance pathways using two processes: physical (mechanical) and 
absorption [RA94].  The three pathways are external (extrinsic), blood and the 
stomach.   
 
Absorption in the fluid of the lung and the subsequent transportation into the 
bloodstream is a two stage process: the dissociation of particles into material that 
can be absorbed in the blood (dissolution) and the absorption of the dissociated 
particles and soluble particles in the blood (uptake).  This absorption process 
(depicted by solubility class) is affected mostly by the chemical properties of the 
inhaled material (see Refs. [EI94] and [DO08]).  Physical properties such as 
particle size are secondary to chemical properties with respect to dissolution.  
Thus, the outcome of inhaled particles is dependent on their physicochemical 
properties [AN99].  After absorption into the blood it is cleared via the kidneys 
into the urine.  The solubility class is further described in Section 2.2.1.2. 
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Mechanical processes are ciliary motion (particle transport) and extrinsic means 
(e.g. nose blowing).  Some are cleared through the airways (ciliary motion), 
swallowed, and excreted in the faeces.  Ciliary clearance leads to transfer to the 
stomach by swallowing.   
 
The different areas in the respiratory tract are depicted in Fig. 2.8.  The ICRP 
Human Respiratory Tract Model (HRTM) consists of four regions: Extrathoracic, 
Thoracic Bronchial, Bronchiolar and Alveolar Interstitial, denoted ET, BB, bb, 
AL, respectively.  
 
 
Figure 2.8: Respiratory tract regions for HRTM (taken from [IC94]). 
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The transfer of radioactive material through the gastrointestinal (GI) tract and the 
uptake in the blood is depicted by Fig. 2.9, the Human Alimentary Tract Model 
(HATM).   
 
 
Figure 2.9: Human alimentary tract model (taken from [IC06]). 
 
Material ingested or cleared from the lungs (ciliary motion) passes through the 
stomach, small intestine, upper large intestine and lower large intestine.  The 
mean transit time (staying time) in the GI tract is very short (1 to 2 days); 
consequently only a small fraction of the ingested material is taken up in the 
blood, mostly from the small intestine.  The uptake fraction depends strongly on 
the solubility of the ingested compound.  Ingested material follows the same route 
as inhaled material (after it has been ingested via ciliary motion).  The above 
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processes are represented by models of uptake and removal with a basic schematic 
depiction given in Fig. 2.10. 
 
 
Figure 2.10: Basic routes after ingestion and inhalation of radioactive material. 
 
2.1.8 Uranium biokinetics 
The basic biokinetic model as modelled by ICRP is explained in the above 
section.  Of specific interest for the present study is uranium and how it behaves 
in the human body.  Inhaled soluble uranium, as described in Ref. [AN07], is 
swiftly transported from the lungs to the blood with most of it being excreted via 
the urine within the first day.  A fraction of the uranium in the blood is deposited 
on bone surfaces where it is retained for several years.  Significant deposits are 
also found in the kidney.  Uranium, like most actinides, is bound in the 
bloodstream by the protein transferrin.  It is deposited primarily in the skeleton 
and the liver.  Some amounts are also deposited in the bone marrow, the spleen, 
muscle and gonads.  The fractional deposition is 22% for the skeleton, 12% for 
the kidneys and 12% on other soft tissues [RA94].  Uranium is a heavy metal and 
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will subsequently damage the kidney tissue due to its chemical toxicity [EI94].  
Uranium uptake may induce renal damage, which leads to renal failure in acute 
uranium poisoning [LE89].  Table 2.5 indicates default solubility classes 
according to ICRP [IC97] for typical compounds found within the uranium 
industry.   
 




F Most hexavalent compounds, e.g. UF6, UO2F2 and UO2(NO3)2 
M 
Less soluble compounds, e.g. UO3, UF4, UCl4 and most other 
hexavalent compounds 
S Highly insoluble compounds, e.g. UO2 and U3O8 
 
The uptake of uranium by the blood from the lungs is significantly slower for 
insoluble uranium, leading to increased radiation exposure (compared to soluble) 
to specifically the respiratory tract.  Subsequently doses to the liver, bone and 
kidneys will be less due to the slower uptake.  The uranium particles remaining in 
the lung constitute a larger potential radiological hazard from the alpha decay 
energy absorbed in the surrounding tissue than particles that are cleared into the 
bloodstream and deposited in the bones and kidneys.  This is due to the longer 
stay time in the lungs and the more sensitive tissue in the lungs [EI94].   
 
The Activity Median Aerodynamic Diameter (AMAD) values depended on the 
specific uranium compounds, the chemical impurities in the compound and the 
manufacturing process.  ICRP recommends using defaults values of 5 µm AMAD 
[IC97].  A review of literature by Rucker [RU01] concluded that the solubility 
rate constant (or rate of dissolution) increases rapidly as the particle size is 
reduced.   
 
 31 
2.2 Workplace characterisation 
The monitoring programme should be determined with consideration of the 
magnitude, possible fluctuations and likelihood of exposure levels [NR04].  Thus, 
is essential that the workplace and the job should be characterized before any 
decisions can be made on a monitoring programme.  A workplace is characterised 
according to: 
• the physicochemical nature of radionuclide compounds found in the 
workplace and  
• the exposure scenarios (spatial, temporal and route) by which the human 
body is internally contaminated.  
 
2.2.1 Physicochemical nature of intake compounds 
The physical (specifically particle size) and chemical nature of a compound will 
dictate where, how much of it and for how long it will be deposited in the human 
body.  The physical nature, specifically it radiological characteristics, will 
determine the radiological burden.  This is one part of the workplace 
characterisation and is essential information in order to develop a monitoring 
programme.  The physicochemical nature of the compound comprises largely of 
the following features: 
• particle size,  
• solubility class and  
• radiological characteristics. 
Each of these features is dealt with in turn below. 
 
2.2.1.1 Particle size (AMAD) 
Activity Median Aerodynamic Diameter (AMAD) is a measure of the particle size 
distribution of airborne radioactive aerosols and particles.  It is that diameter of 
which fifty percent of the aerosol’s activity is greater than the AMAD.  Particle 
size determines the pulmonary pattern and, therefore, the associated radiological 
hazard from inhalation [CE96].  The AMAD combined with the breathing rate 
and whether the person is a nose or mouth breather determines the fractional 
deposition in each region of the respiratory tract.   
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Reference [DO95] stresses the importance of having realistic parameters for use in 
radiation dose assessments and thus recommends that particle size distribution 
should be measured for individual work practices.  This type of study is outside 
the scope of the present research project.  Default particle sizes which are 
characterized by AMAD values should only act as a guide if detailed information 
is not available.  Inhaled aerosols could be due to particles generated from a 
process or from resuspended surface contamination.  Resuspended aerosols tend 
to have larger AMAD values typically in the order of 6 µm.  
 
2.2.1.2 Solubility class 
Inhaled aerosol material is classified according to their clearance from the lungs.  
These classifications refer to the length of time particles from inhaled aerosols are 
retained in the pulmonary region [IC97].  Inhaled material is classified either as 
Type S, M or F.  The stay time of inhaled particles has a significant impact on the 
committed effective dose.  Chemical form determines solubility and consequently 
transportability in body fluids.  The transportability of inhaled or ingested material 
determines its fate within the body and, therefore, the resulting radiation dose. 
 
The monitoring of inhaled radiological contaminants is based on an understanding 
of the lung solubility of inhaled contaminants that are present at a facility [RU01].  
Literature recommends that solubility studies be performed, but have been shown 
to be complicated to measure [DO04].  This type of study is again outside the 
scope of the present research project.  The three classifications for absorption rates 
expressed as half times (see Section 2.1.7) are defined as follows [IC97]: 
 
Type F (Fast):  100% absorbed with a half-time of 10 minutes 
 
Type M (Medium): 10% absorbed with a half-time of 10 minutes and 90% is 
absorbed with a half-time of 140 days 
 
Type S (Slow): 0.1% absorbed with a half-time of 10 minutes and 99.9% is 
absorbed with a half-time of 7000 days. 
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As can be seen, these three classes are very broad and range from minutes to days 
to several years.  Therefore, knowing the solubility of intake particles to which 
exposure is possible is of vital importance when determining how to protect 
workers, with less soluble materials posing a greater radiological exposure hazard. 
 
2.2.1.3 Radiological characteristics 
The radiological characteristics of an isotope are defined amongst others by its 
type of decay (including energy of decay radiation), half-life and activity 
(including activity composition: mass enrichment).  These characteristics play an 
important role in the calculated CED and the monitoring programme.  
Radiological characteristics are discussed in Section 2.1. 
 
2.2.2 Exposure scenario 
The exposure scenario provides information that will assist in determining the 
monitoring programme and assist in calculation of CED.  It can be described 
according to the following attributes: 
• spatial (sources of intake), 
• pathway (routes of intake) and 
• temporal (time of intake) 
Each of these attributes is discussed in turn below. 
 
2.2.2.1 Sources of intake (spatial) 
Information such as where intake occurs and what the sources are represents the 
essential basic information needed.  This will aid in developing control measures 
to prevent intake and to characterise intake.  Based on the processes involved, one 
can determine which nuclides workers are exposed to and what will be the 
possible route of intake.  Processes will determine whether there is a significant 
risk of internal intake and whether it should be monitored.  Dry processes most 
probably will lead to material becoming airborne.  If these processes are not 
contained it could result in inhalation of the material.  Loose contamination being 
resuspended and becoming airborne is also a major source of exposure.   
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Contamination control plays an important role in the overall effectiveness of a 
radiological control programme in respect of internal exposures.  Loss in 
containment will result in surface contamination and airborne dispersion that 
could lead to uptake of nuclides and subsequently to internal exposures.  Airborne 
contaminants are continuously removed from the work place with the aid of a 
ventilation system and filtration.  Contamination control is also provided by 
protective clothing and respiratory protection. 
 
Information gained from determining the spatial characteristics of the exposure 
will aid in determining the monitoring programme, specifically the monitoring 
technique. 
 
2.2.2.2 Routes of intake (pathway) 
The route of intake can be by inhalation, ingestion, through a wound or injection 
or a combination these pathways.  In Ref. [LE10] it was found that significant 
errors occur if only one intake route is assumed and that there were significant 
variations in the CED if different routes of intake are assumed.  Thus, it is 
important to know the most likely route of intake and in cases of a significant 
intake is expected one should be as specific as possible.  For routine monitoring, 
one intake path is usually assumed.  This assumption can lead to high 
uncertainties.   
 
In routine monitoring situations the pathway will most likely be inhalation, but it 
could also be ingestion or a combination of inhalation and ingestion.  However, in 
Ref. [ID06] it was proposed that ingestion should be assumed only in those cases 
where there is clear evidence for this pathway (well established and documented).  
Otherwise the inhalation pathway should be assumed. 
 
Information gained from determining the route of intake will aid in determining 
the monitoring programme (specifically the monitoring technique) and aid in the 
CED calculations. 
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2.2.2.3 Time of intake (temporal) 
In Ref. [ID06] time of intake is categorised and defined as follows: 
 
Acute intake: An intake occurring within a time period short enough that it can 
be treated as instantaneous for the purposes of assessing the 
resulting committed dose. 
 
Chronic intake: An intake over an extended period of time, such that it cannot be 
treated as a single instantaneous intake for the purposes of 
assessing the resulting committed dose. 
 
Information gained from determining the time of exposure will assist during CED 
calculations.  Dose conversion factors for routine exposures in Ref. [IC97] are 
based on the assumption of an acute intake in the middle of the monitoring period.  
An intake in the middle of the monitoring period is also the default 
recommendation if the time of intake is unknown or if the exposure is chronic.  
Latest software available is capable of modelling true chronic intakes, thus 
negating the default recommendation of the ICRP. 
 
2.3 Monitoring programme 
A monitoring programme is divided into three monitoring strategies viz. routine, 
task related or special monitoring.  The location of the monitoring is at the 
workplace (e.g. static air samplers) and at an individual level (e.g. passive air 
monitors, bioassay protocols).  Workplace and individual monitoring are 
complementary to each other.  Workplace monitoring will provide basic 
information needed to develop a programme of individual monitoring.  Individual 
monitoring consists mainly of bioassay protocols, which are supported by 
personal air monitoring and workplace air monitoring.  The bioassay technique 
and frequency will be decided by physiochemical nature (decay method, effective 
half-life, solubility etc.) of the nuclide that needs to be detected, its biokinetic 




The objective of the OMINEX Project [ET03] is to enable users to optimise the 
design and the implementation of a monitoring programme.  This includes, 
amongst other possibilities, the choice of monitoring methods, measurement 
techniques monitoring intervals, monitoring frequencies and measurement 
sensitivity. 
 
2.3.1 Monitoring strategies 
There are three types of monitoring strategies which are described in Ref. [IA99b] 
as follows: 
 
1) Routine or Confirmatory Monitoring 
“It is associated with continuing operations and is intended to 
demonstrate that the working conditions, including the levels of individual 
dose, remain satisfactory, and to meet regulatory requirements.  It is thus 
largely confirmatory in nature, but underpins the overall operational 
monitoring programme.  Routine monitoring programme are made at pre-
determined times which is not related to known intakes, and therefore it is 
necessary to make some assumptions about the pattern of intakes.” 
 
2) Task Related Monitoring 
“It applies to a specific operation.  It provides data to support the 
immediate decisions on the management of the operation.  It may also 
support the optimization of protection.  In these cases, the time of intake or 
potential intake is known and workplace monitoring may provide 
additional information on the physical and chemical nature of any 
contamination.” 
 
3) Special Monitoring 
“It is investigative in nature and typically covers a situation in the 
workplace for which insufficient information is available to demonstrate 
adequate control. It is intended to provide detailed information to 
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elucidate any problems and to define future procedures. It should 
normally be undertaken at the commissioning stage of new facilities, 
following major modifications either to facilities or procedures, or when 
operations are being carried out under abnormal circumstances such as 
an accident.” 
 
The focus of the present study is on routine monitoring.  Thus, it is essential to 
note that this monitoring strategy is made at predetermined times which are not 
related to a known intake.  Assumptions with respect to time of intake are made 
and the impact thereof will be discussed in the latter part of the study.  Task 
related and special monitoring are excluded from the present study. 
 
2.3.2 Location of monitoring techniques 
Monitoring is done at two distinct locations.  In Ref. [IA99b] the locations are 
described as follows: 
 
1) Workplace Monitoring 
“Workplace monitoring comprises measurements made in the working 
environment.”   
 
2) Individual Monitoring 
“Individual monitoring is taken to mean measurement by equipment worn 
by individual workers, or measurement of quantities of radioactive 
materials in or on their bodies, and the interpretation of such 
measurements.”  
 
Typical workplace monitoring techniques are airborne contamination monitoring 
such as Static Air Samplers (SAS) alternatively known as Continuous Air 
Monitors (CAM) and surface contamination monitoring.  Typical equipment worn 
includes personal air samplers and measurement of material in the body is 
grouped as bioassay techniques.  The focus of the present study is on individual 
monitoring.   
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2.3.2.1 Workplace monitoring 
Workplace monitoring should be used to trigger a programme of individual 
monitoring.  It includes requirements such as the placing strategy of air samplers.  
Air samplers should be strategically placed; viz. placed where it is representative 
of the air breathed by workers (if it is to be used for internal dose calculations) or 
placed where it is representative of the average air concentration of a workplace.  
Workplace monitoring and an IDMP are complementary to each other.  However, 
the requirements for workplace monitoring are not within the scope of the present 
study. 
 
2.3.2.2 Individual monitoring 
Bioassay is defined as any procedure used to determine the nature, activity, 
location or retention of radionuclides in the body by direct (in vivo) measurement 
or by indirect (in vitro) analysis of material excreted or otherwise removed from 
the body [IA99a].  In-vivo and in-vitro monitoring can thus also be grouped as 
individual monitoring.  Other methods to determine internal contamination are by 
monitoring the airborne contamination.  This includes personal air sampling (also 
classified as individual monitoring) and static air sampling (classified as 
workplace monitoring).   
 
The order of preference for bioassay is direct body activity measurement (in-vivo), 
excreta analysis (in-vitro) and then personal air sampling [IC97]. 
 
In-Vivo monitoring 
In-vivo monitoring is the direct monitoring of γ-ray emitting radionuclides taken 
up in the whole body or certain organs [SC03].  Counting activity in a body is 
only possible for nuclides emitting radiation that can escape the body.  These are 
usually gamma emitters such as fission and activation products (e.g. 131I, 137Cs, 
60Co and 99Mo/99mTc).  These methods can also be used to determine the uptake of 
low-energy photon emitters such as long-live alpha emitters (235U, 239Pu and 
241Am).  The types of monitoring techniques available for body activity counting 
are Whole Body Counting, Lung Counting, Thyroid Counting and Skeleton 
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Counting (knees and skull).  Advantages are that it can be used for routine 
monitoring since it is direct, quick and a convenient measurement.  Monitors 
(usually scintillator based detectors) with energy discrimination capability are 
necessary in cases with a mixture of radionuclides.  In-vivo techniques are 
generally more accurate than in-vitro techniques because they do not rely on 
metabolic information that is required to determine excretion rates of nuclides.  
They are also more able to monitor for insoluble nuclides that are not readily 
dissolved and excreted.  It has the disadvantage that equipment could be 
expensive (e.g. massive shielding, large detectors) and external contamination can 
be mistaken as a true intake.   
 
In-Vitro monitoring 
In-vitro monitoring is the indirect monitoring of radionuclides taken up in the 
body.  The activity in the body is inferred from analysing material excreted or 
removed from the body.  This method is used for radionuclides that emit no γ-rays 
or very low energy γ-rays that cannot be detected with in-vivo counting [SC03].  It 
is in most cases not interpreted quantitatively, but rather used as confirmation of 
satisfactory conditions [IC97].  Uncertainties associated with in-vitro monitoring 
are very high since the excretion functions for many radionuclides are not well 
known and there are large variations in excretion rates between individuals 
[SC03].  Typical excreta that are analysed are: 
• faeces, 
• urine, 
• blood and 
• other e.g. nose blows, breath, hair and nails etc. 
In-vitro monitoring has a further disadvantage since it is unpleasant and requires 
samples of urine and faeces.   
 
The chemical and physical form (physiochemical nature) of the material 
determines its behaviour on intake and its subsequent biokinetic behaviour in the 
human body, which will determine the route of excretion and subsequently the in-
vitro technique to be used.   
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Faeces excretion has two components (see Refs. [IA99a], [ID06]):  
• systemic faeces excretion which represents removal of systemic material 
via the Gastro Intestinal (GI) tract and  
• direct faeces excretion of the material passing unabsorbed through the GI 
tract. 
It is used for monitoring insoluble material such as Type-S or Type-M material 
ingested from the respiratory tract.  Faeces should be collected over a period of 
several days, which could be impracticable.  Uncertainties are high due to the 
daily fluctuations in faeces excretions.  Consequently, the accuracy is mostly 
larger than a factor of 2.  This technique is used in combination with urine 
analysis and lung counting.  It is not usually done routinely and more often used 
in special monitoring due to above mention impracticalities and uncertainties. 
 
Urine analysis is based on the removal of material from the plasma and extra 
cellular fluid.  It is mostly used for soluble material, but can also be used for 
insoluble material.  Typical radionuclides monitored are tritium (β- emitter) and 
uranium compounds (see Refs. [NR04] and [ID06]). 
 
The recommendation in Ref. [IA99] is to analyse blood in accident situations in 
which large intakes are suspected.  This can provide data on the solubility and the 
biokinetic of the material involved, but has limited value for providing 
quantitative estimates of the intake at low doses. 
 
Other excreta analysis includes nose blows, nose smears and exhaled breath.  
Typical nuclides monitored are 14C, or 232Th daughters, 220Rn, 226Ra and 228Th.  
Measuring nose blows and nasal smears can be used as screening techniques in 
suspected incidents [IC97].  By using regional deposition fractions (fraction 
deposited in nose during inhalation), an estimation of the intake can be made.  
Analysis of hair and nails can provide additional information with respect to 
temporal distribution of intake [KA01].  
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Personal Air Samplers (PAS) 
In Ref. [LO07] an internal dosimetry programme based on air sampling is 
described as the collection of a representative air sample. The air sample is 
representative of the activity concentration in the air inhaled by a worker.  This 
allows the estimation of CED based on time exposed to the measured air 
concentration.  Air samples can be taken with either personal air samplers or 
workplace samplers.  
 
2.3.3 Monitor frequency and sensitivity 
The frequency of monitoring will depend on the rate of retention and excretion of 
the radionuclide (biological half-life), the physical half-life, the sensitivity of the 
measurement technique and the acceptable uncertainty in the CED.   
 
The chemical and physical form (physiochemical nature) of the material 
determines its behaviour on intake and its subsequent biokinetic in the human 
body, which will determine the stay time within the human body and subsequently 
the rate of excretion.  This is characterised by the biological half-life of the 
nuclide.  Effective half-life is defined (see Section 2.1.1) as the combination of 
physical half-life (radioactive decay) of the nuclide and the biological half-life 
(biological clearance).   
 
In setting a schedule, one should ensure that an intake above a predetermined 
level is not ‘missed’.  An intake could be missed if the measured activity were to 
decline to a level below the sensitivity of the measurement technique during the 
time interval between the intake and the measurement.  This is determined by the 
effective half-life of the nuclide.  Thus, frequency of monitoring will also be 
driven to a great extent by the sensitivity of the measurement technique. 
 
In Ref. [IA99a] it is proposed that the intervals of measurement are typically set 
so that intakes corresponding to >5% of the projected annual dose limit are not 
missed.  The annual dose limit for whole body exposure is 20 mSv, as set by the 
ICRP [IC07].  The projected annual missed dose should thus not be more than 1 
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mSv (5% x 20 mSv).  This is similar to the recording level set in Ref. [IC88] at 
10% (2 mSv) of the annual dose limit.  In Ref. [AN01] it is recommended that 
screening levels be significantly lower than this.  The recommendation in Ref. 
[NR04] is to use 1 mSv, since a worker is only defined as a radiological worker if 
the annual dose exceeds 1 mSv.  These levels can be seen as the maximum 
Decision Level (DL).  This required sensitivity or required frequency can be 
calculated as follows: 
 
Sensitivity (mSv) = 1 mSv x MPe (days)365 (days)  
 (2.11) 
and   
MPe (days) = 1 mSv x Sensitivity (mSv)365 (days)  , 
(2.12) 
where 
MPe = Monitoring Period (frequency) 
l mSv = Maximum DL (missed dose) 
 
Derived sensitivity values (derived decision levels) can be calculated based on the 
equivalent of 1 mSv viz. µg/ℓ or Bq/ℓ for urine monitoring (total uranium) and Bq 
for lung monitoring (only 235U).  
 
Routine bioassay measurement periods longer than five effective half-lifes are 
generally not recommended, because the potential individual specific deviations 
from assumed retention or excretion patterns can substantially affect associated 
doses.  Five effective half-lifes imply that the original intake has decreased to 3% 
(0.55) of its original value.  Furthermore, the sampling schedule (monitoring 
period) should also minimize the uncertainty in the estimated intake due to the 
unknown time of an intake within the monitoring period.  In Ref. [IC97] it is 
recommended that monitoring periods should generally be selected so that 
assuming an intake to have occurred at the mid-point of the monitoring period it 
would not lead to an underestimation of the intake by a factor of more than three.  
This is in relation to the most conservative intake, viz. an intake on the 1st day of 
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the monitoring period.  A solution for this is suggested in Ref. [ST03] and is 
discussed further in Section 3.3.3. 
 
In order of preference, the criteria to be used for determining the frequency for a 
routine monitoring strategy are set out as follows: 
• projected annual missed effective dose to 1 mSv, 
• underestimation of calculated CED less than a factor 3 and 
• practicality. 
 
2.4 Internal dosimetry 
Internal dosimetry is the scientific methodology used to calculate the activity 
retained in the human body and the resultant committed effective dose.  Different 
doses can be calculated from the same set of measurement date due to several 
physical and human metabolic parameters that can vary significantly.   
 
2.4.1 Committed Effective Dose (CED) calculation steps 
In general a CED is calculated as follows: 
 
Step 1: Bioassay measurement. Typical units are Bq in lungs, whole body or 
thyroid, and Bq/ℓ for urine.  In essence, this is representative of the 
uptake.  The uptake in a body part (organ) is determined from direct 
measurement of the organ (e.g. lung counting) or derived indirectly from 
excreta measurement (e.g. uptake in blood derived from activity 
measurements in urine). 
 
Step 2: Calculate intake.  Assume a route of entry and using the biokinetic 
behaviour of the nuclide, back calculate the intake from the measurement 
point (e.g. urine, lungs). Correct also for time of measurement, viz. 
correct for physical and biological decay. 
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Step 3: Calculate CED.  Using the biokinetic behaviour of the intake nuclide, 
determine the distribution in the body and stay time in the various organs.  
Calculate CED using Eq. (2.8). 
 
2.4.2 The philosophy of internal dosimetry 
The basic philosophy for internal dosimetry was formulated by Project IDEAS 
[ID06]. It states: 
 
“internal dosimetry, as in external dosimetry, the philosophy is that if two 
persons have the same internal exposure then the results of internal 
monitoring in terms of committed dose should be consistent (harmonised) 
with each other, and the results should be considered to be the best 
estimate (accurate).  This entails a consistent approach to dose evaluation 
and the approach should lead to a best estimate.  In cases of uncertainties 
it is more important to ensure that the committed dose is unlikely to exceed 
a specific level.”   
 
For a given set of internal monitoring data in terms of body/organ activity and/or 
urine/faeces activity there should be one standard estimate for the intake and the 
committed effective dose.  This standard estimate is defined by the monitoring 
data, the biokinetic models, dosimetric models, and some additional information, 
such as time of intake, route of intake, particle size, respiratory tract absorption 
type (solubility), etc.  Recent previous internal exposures should also be taken into 
account. 
 
The aim of Project IDEAS is thus to develop general guidelines for standardising 
assessments of intakes and internal doses [DO07].  Project IDEAS [ID06] 
proposed the following guiding principles: 
 
1) Harmonisation 
Any two assessors should obtain the same estimate of dose from a given 




The best estimate of dose should be obtained from the given data set.   
 
3) Proportionality (Graded Approach) 
The effort applied to the evaluation should be proportionate to the dose.  
The higher the dose, the more complex the approach should be and the 
lower the dose, the simpler the process. 
 
Together the three principles will guide the formation of a standard estimate.  This 
is detailed below.  
 
2.4.2.1 Graded approach 
The effort applied to the evaluation should be proportional to the dose [DO07].  
As doses increase in magnitude, sufficient measurement results and workplace 
characterization data (physiochemical nature and exposure scenario) should be 
obtained in order to make adjustments to the models.  This is to account for the 
unique behaviour of the radionuclides in the individual’s body.  Reference dose 
levels should be established which require enhancement of data collection and 
individual specific dose assessment efforts.  A graded approach, with increasing 
level of complexity, was developed by Project IDEAS [ID06] and is described 
below.   
 
2.4.2.2 Harmonised and accurate 
Harmonising is achieved by following proper written procedures.  Project IDEAS 
has developed a standard approach when estimating a dose.  This approach is 
described in detail in the following section.  In the case of routine monitoring, 
usually based on a single measurement, the procedure is simple.  In instances 
where there are several measurements from different techniques, it can lead to 
different ways of handling data and subsequent different doses.  In these cases, 
harmonisation is achieved by a systematic approach in handling data and 
changing parameters.   
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This standard and systematic approach becomes more complex as the dose 
increases [ID06].  Such a multifaceted approach ensures higher level of accuracy 
as the dose increases.  Uncertainties associated with assessed internal dose can be 
significant.  This is especially the case for actinides which are difficult to detect in 
the body and which have relatively high dose coefficients (SvBq-1).  Thus, it is 
important to make best use of the available information. 
 
The ICRP has recently developed more realistic internal dosimetry models, 
namely the HRTM, HATM and recycling systematic models for actinides.  
However, these guidelines leave many assumptions open for interpretation, i.e. 
when to use assumed default values [DO07].  The biokinetic models, although 
realistic, are based on standard metabolic models and, therefore, do not 
necessarily reflect the true effect of uranium uptake in a real person.  An 
individual’s metabolism will not necessarily agree with this model.  This leads to 
significant differences from using defaults values when calculating doses.  A 
warning was given in Ref. [DO07] that these default values may not be valid in 
specific situations.  Thus, it is important to understand the effect of using default 
parameters and the uncertainties associated with them.  Preferably, assumptions 
should be more individual and exposure specific, especially when intakes have a 
significant dose impact.  Guidance is needed on which ICRP default parameters 
are reasonable to change.  This guidance is provided by Project IDEAS [ID06].  
 
The aim is to change default values until a best fit is found.  A measure of the 
“Goodness of fit” (GOF) and the criteria for deciding that the fit is good enough 
are critical.  There may be conflict between “harmonisation” and “accuracy” 
[ID06].  The more generic an approach is (to ensure harmonisation) the less 
accurate it may be.  Generally, the better the data (quality and quantity) the more 
likely it is that a statistical test will show that the data are inconsistent with the 
default model.  Less data will probably fit the model easier.  In the case of a single 
measurement any model will fit.  Thus, it is important to ensure there are 
sufficient data for assessment of a significant dose.  The default parameters are 
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changed and subsequently the default model.  This is done in a systematic way till 
the model fits the data. Several statistical methods (maximum likelihood method, 
the Bayesian approach) for data fitting are available [IA04b].  Typical default 
parameters include the physiochemical properties (AMAD, solubility) of the 
intake nuclide and the exposure scenario of the intake (route and time of intake).  
It is the aim of the present study to investigate the effect of these parameters on 
the CED.  
 
2.4.3 The standard estimate for internal dosimetry 
Together the three principles studied above guide the formation of a standard 
estimate.  This standard estimate follows a graded approach ensuring accurate and 
harmonised calculation of CED.  In Ref. [ID06] the following standard estimate is 
recommended:  
 
Level 0: Annual projected CED most likely < 0.1 mSv 
•  CED need not be calculated; 
• measured value should be recorded (could be needed for further 
assessments in the future); 
• implies typical measured doses for the following monitoring 
period:  1 month (~8 µSv); 3 months (~25 µSv) and 6 months 
(~250 µSv).   
 
Level 1: Annual projected CED between 0.1 – 1 mSv; 
•  uncomplicated CED calculation based on ICRP default parameters; 
•  a priori information such as AMAD can be used if available. 
 
Level 2: Annual projected CED between 1 – 6 mSv; 
•  perform a realistic assessment of dose; 
• typical parameters to be adjusted relates to the material (AMAD 
and absorption type) and exposure scenario (time of intake); 
•  obtain a reasonable fit with predicted data. 
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Level 3: Annual projected CED > 6 mSv; 
•  comprehensive set of measurement data is needed; 
• typically parameters to be adjusted relates to the individual e.g. 
HRTM particle transport rates in case of inhalation (including 
parameters relating to the material and the exposure scenario); 
• systematically change default model parameters until fit is 
acceptable to all of the data; 
• provide valid justification for rejected data. 
 
The annual projected dose is accumulated over a period of 12 months assuming 
similar intakes in each monitoring period (MPe) and is given by.  
 
Annual projected CED = Measured dose x Number of MPe per year. (2.13) 
 
The above levels should be used for doses for a specific period as well as 
accumulated doses for several consecutive periods.  Thus, re-evaluate a previous 
period’s dose according to the next level should the accumulated dose for 
successive periods be in a higher level. 
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CHAPTER 3  
DEVELOPMENT OF URANIUM MONITORING 
PROGRAMME. RESULTS, DISCUSSION AND 
RECOMMENDATIONS 
 
Airborne workplace exposure to radioactive substances should be characterised by 
taking into consideration all available information regarding the physical and 
chemical (physiochemical) nature of the airborne contamination.  This includes 
the spatial and temporal distribution of the exposure, where and when the intake 
occurs and the route of intake (exposure scenarios).  Based on such information, 
for the present study a monitoring programme for uranium will be developed.  To 
this end, in the first part of this chapter simulated bioassay measurements are 
generated in order to evaluate the effect of changing input parameters and default 
values.  The aim is to quantify the sensitivity of the Committed Effective Dose 
(CED) calculation for changing parameters and to determine which parameters are 
important (sensitivity analysis).  In addition, it will provide an understanding of 
the uncertainties associated with reported CED values and, when using a graded 
approach, one will also know which parameters will lessen uncertainties and 
provide a more accurate estimate of the CED.  Based on the above and a literature 
survey, this chapter will provide recommended physicochemical values and aims 
to describe the complexity of exposure scenarios within a uranium plant.  It is not 
within the scope of the present study to experimentally determine the 
physicochemical nature of the uranium exposures.  As reported in the literature 
research it has been shown that these types of experiments can be extremely 
complex and complicated and requires a study on its own.  Therefore, it was 
decided to pursue a literature study for similar exposure situations and use the 
literature recommended values as applicable.  As such, typical processes and 
uranium compounds found within a uranium recovery and uranium alloy 
manufacturing plant will be described.  In order to develop a site-specific uranium 
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monitoring programme, a literature study was done on various bioassay 
techniques used in various other programmes.  The results were then compared 
with bioassay techniques used by Necsa and the limitation of the various 
techniques determined and discussed.  The specific characteristics (e.g. 
sensitivity) of the various techniques were investigated.  Using the above 
information as input, including literature study of uranium specific bioassay 
programmes, an individual monitoring programme for Type M uranium was 
developed for Necsa based on the guiding principles in Chapter 2.   
 
3.1 Physiochemical nature of intakes 
The physicochemical nature of the compounds found within a uranium plant can 
be described by the following characteristics: 
• particle size, 
• solubility class and 
• radiological characteristics. 
Each of the above are dealt with in turn below. 
 
3.1.1 Particle size (AMAD) 
Default particle sizes, characterized by Activity Median Aerodynamic Diameter 
(AMAD) values should only act as a guide if detailed information is not available.  
Actual determination of AMAD values is not part of the present study.  As such, a 
literature survey for recommended AMAD values was undertaken and these 
values were used as applicable.  The effect of AMAD on CED and intake values 
will be shown first where after the variances in typical AMAD values will be 
discussed.  For the sake of intercomparison, all figures and tables are shown 
together at the end of this section. 
 
3.1.1.1 Effect on CED per unit intake 
Hegyi has shown the considerable effect of AMAD on CED [HE08].  For Type S 
234U, the ratio of CED between 0.4 µm and the default of 5 µm AMAD is 1.5 and 
the ratio of CED between 13 µm and the default of 5 µm AMAD is 0.5.  This is 
for a fixed unit intake values (1 Bq/day) irrespective of the monitoring technique.  
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This can be seen in Fig. 3.1 and Table 3.1, as confirmed by calculations done by 
the author.  Similar values were found by Dorrian [DO95].  A calculated CED can 
thus change up to 200% as the AMAD is changed.  The same effect was found for 
Type M uranium as can also be seen in Fig. 3.1 and Table 3.1.  The overall trend 
is that the radiological risk and resultant CED decreases as the AMAD increases, 
as illustrated in Fig. 3.1.  The CED initially decreases with increasing particle size 
up to about 0.6 µm [KI05].  Thereafter, it slightly increases with particle size up to 
about 2.5 µm and decreases again [HE08].  Particles that dissolve easily into the 
bloodstream pose a lower radiological hazard due to the smaller stay time in the 
lungs and is in agreement with the statements in Section 2.1.8 concerning uranium 
biokinetics.  The solubility rate constant (or rate of dissolution) increases rapidly 
as the particle size is reduced [RU01].  It should be noted that the particle size of 
interest for a uranium plant is between 4 - 9 µm.   
 
3.1.1.2 Effect on intake value per unit bioassay measurement 
The previous section has shown the variance in the calculated CED (for a fixed 
unit intake) as the AMAD is changed.  This section describes the variance in the 
calculated intake value as the AMAD is changed.  The extent of the variance is 
also dependent on the type of monitoring technique.  The intake is calculated from 
the measured bioassay value (using biokinetic models) and thus is dependent on 
the monitoring technique (see the basic steps for CED calculations in Section 
2.4.1).  This is especially so for monitoring methodologies that depend on lung 
counting and was shown to be the case for Type S 239Pu and Type M 241Am by 
Fujita [FU03].  In the present work, similar calculations were done for Type M 
uranium for urine analysis and lung counting and the results are shown in Fig. 3.2 
and Table 3.2.  The results corroborate with literature values, indicating a 
significant dependence for both urine analysis and lung counting with lung 
counting the most sensitive to changes to changes in AMAD. 
 
3.1.1.3 Effect on CED per unit bioassay measurement 
As can be seen above, the CED calculations are strongly negatively dependent on 
AMAD for a fixed intake value.  The CED values decrease with increasing 
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AMAD values.  In contrast, the intake calculation is strongly positive dependent 
on the AMAD for a fixed bioassay measurement.  The combined effect of these 
two calculations is shown in Fig. 3.3 and Table 3.3. 
 
This dependence is less severe for the combined calculation, urine analysis and 
lung counting.  It should be noted that the CED is significantly less dependent on 
AMAD for monitoring based on urine analysis except for very small AMADs (1 
µm) and the over and under estimation is ~ 4% (submicron particles are not 
expected in a typical uranium plant).  The largest deviation from the default 
AMAD (5 µm) is 0.93 for AMAD of 6.5 µm.  As such, AMAD does not need to 
be considered for monitoring programs based on urine analysis and the ICRP 
default value of 5 µm can be used. 
 
In the case of lung counting, the over estimation is significant for AMADs larger 
than 6 µm.  For AMADs between 4 µm and < 8 µm the effect on CED is within ± 
5%.  Very small (< 4 µm) or large (> 9 µm) AMADs are unlikely in a uranium 
plant environment, as can be seen in Table 3.5.  Large AMAD values close to 8 
µm are found for U3O8, which can lead to severe underestimation (~ 33% as from 
Table 3.3) if the default ICRP value of 5 µm is used.  Although submicron 
particles are not expected in a typical uranium plant, there is a possibility that high 
temperature operations may produce submicron aerosols [DO95].  As such, 
AMAD does not need to be considered for monitoring programs based on lung 
counting and the ICRP default value of 5 µm can be used, except in cases where 
U3O8 is used or in high temperature operations.  In these instances it is advised to 
determine the actual AMAD values. 
 
3.1.1.4 Determining AMAD values from the lung/faeces ratio 
AMAD values can be determined from the lung/faeces ratio.  This was done for 
an intake of Type M 241Am [FU03].   The ratios were calculated from lung and 
faecal measurements taken on day 5 after an acute intake.  Similar calculations 
were done for Type M uranium and are shown in Fig. 3.4 and Table 3.4.  Faeces 
excretion shows strong variation between individuals for the 1st week after an 
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intake.  As such, the lung/faeces ratio should be determined with measurements 
taken 5 or more days after intake.  This ratio should be used as an indication of 
significant deviations from the ICRP defaults value of 5 µm.   
 
3.1.1.5 Typical AMAD values 
The AMAD values depend on the specific uranium compounds, the chemical 
impurities in the compound and the manufacturing process.  ICRP recommends 
using defaults values of 5 µm AMAD [IC97].  A study done by Ansoborlo 
[AN02] found AMAD values varied between 1.1 µm and 8.5 µm with an average 
at 5.7 µm (± 1.9 µm).  This finding is for all uranium compounds found in various 
uranium processing industries in France.  Typical AMAD values for compounds 
found in French uranium plants are given in Table 3.5 [AN02]. 
 
In addition, Ansoborlo [AN02] also compared the AMAD average of 5.7 µm (± 
1.9 µm) with two other studies (4 µm and 5.5 µm) and found reasonable 
similarities (see Refs. [AN97] and [DO95]).  Consequently, Ansoborlo supported 
the AMAD default value of 5 µm as recommended by the ICRP.  Dorrian [DO95] 
did a literature research on average AMAD value published for various work 
environments and found a median of approximately 4 µm for nuclear fuel-
handling industries and subsequently also supported the ICRP default AMAD. 
 
The importance of AMAD has been indicated in the above mentioned literature as 
well as in calculations done by the author.  Following a graded approach, the 
default ICRP AMAD value will be acceptable for routine Type M monitoring 
(lung counting and urine analysis).  The recommended default ICRP values are 
representative of the inhaled aerosol and do not significantly under- or over-
estimate dose for AMAD values between 4 µm and 8 µm.  However, more 
accurate AMAD values should be used for intakes of U3O8 if the intakes are close 




Figure 3.1: CED dependence on AMAD (fixed intake). 
 
Table 3.1: CED dependence on AMAD (fixed intake). 
 
Normalised CED a) 
AMAD 
(µm) 
Type M Type S 
0.4 1.93 1.67 
1 1.49 1.33 
4 1.14 1.17 
5 1.00 1.00 
8 0.81 0.78 
13 0.49 0.50 
a) Calculations were done with IMBA assuming: 
• chronic intake over 28 days, 
• CED normalised to ICRP default AMAD value of 5 µm, 
• low enriched (IMBA Values: 3.5%) and  
• fixed intake of 1 Bq/day intake. 
 55 
 
Figure 3.2: Intake dependence on AMAD (fixed bioassay measurement). 
 
Table 3.2: Intake dependence on AMAD (fixed bioassay measurement). 
 
Normalised Intake a) 
AMAD  
(µm) 
Lung Counting Urine Analysis 
1 0.52 0.78 
4 0.83 0.91 
5 1.00 1.00 
6 1.19 1.08 
8 1.65 1.26 
9 1.92 1.35 
a) Calculations ware done with IMBA assuming: 
• chronic intake over 28 days, 
• Intake normalised to ICRP default AMAD value of 5 µm, 
• 1 Bq measured in lungs on day 30 and 
• 1 Bq/day measured in urine sample on day 30. 
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Figure 3.3: CED dependence on AMAD (fixed bioassay measurement). 
 
Table 3.3: CED dependence on AMAD (fixed bioassay measurement). 
 
Normalised CED a) 
AMAD  
(µm) 
Lung Counting Urine Analysis 
1 0.77 1.16 
4 0.95 1.04 
5 1.00 1.00 
6 1.03 0.93 
8 1.33 1.02 
9 1.38 0.97 
a) Calculations were done with IMBA assuming: 
• chronic intake over 28 days, 
• CED normalised to ICRP default AMAD value of 5 µm with 
• 1 Bq measured in lungs and 1 Bq/day measured in urine sample on day 30. 
 
 Figure 3.4: Faeces excretion 
 









a) Calculations were done with IMBA assuming:
• acute intake 5 days prior,
• low enriched (IMBA values
• 1 Bq intake. 
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versus lung content ratio for different AMAD.
versus lung content ratio for different AMAD.













at day 5 a) 
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U3O8 5.6 / 5.9 / 6.7 / 8.3 / 8.5 
UF4 4.2 / 5.1 / 5.8 
 
3.1.2 Solubility class 
The recommendation in literature is that solubility studies should be performed, 
but it has been shown difficult to measure [DO04].  Since this type of study is 
outside the scope of this research project, a literature survey was undertaken with 
a view to using determined values as applicable.  Here solubility class and the 
subsequent stay time in the lungs plays a significant role in the calculated CED as 
described in Section 2.1.8 concerning uranium biokinetics.  
 
3.1.2.1 Default solubility classes 
Table 3.6 indicates default classes according to ICRP [IC97] for typical 
compounds found within the uranium industry.  Normally found in a uranium 
plant are UAl3, UO3, UO2(NO3)2, UF4, UO2, UO3.H2.O.NH3 and U3O8.  As 
described in Section 2.2.1, the absorption rate varies significantly between the 
three classes, from minutes to days to several years 
 




F Most hexavalent compounds, e.g. UF6, UO2F2 and UO2(NO3)2 
M 
Less soluble compounds, e.g. UO3, UF4, UCl4 and most other 
hexavalent compounds 
S Highly insoluble compounds, e.g. UO2 and U3O8 
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3.1.2.2 Effect on CED 
Here it should be noted that between solubility classes there are significant 
variances in CED.  This is due to the large variances in absorption rate between 
the solubility classes and the effect on CED can be seen in Table 3.7.  An 
incorrect solubility class for routine monitoring based on only urine samples can 
lead to under- or over-estimation by a factor of 1600 (0.0006/1) between Type F 
and S, a factor of 15 (0.0006/0.01) between Type F and M and a factor of 100 
(0.01/1) between Type M and Type S.  The under- or over-estimation is less 
severe with lung counting.  It is a factor 2.1 (1/0.48) between Type M and S. Type 
F is not considered for lung counting due to the fast clearance from the lungs.  
The large variances in CED for urine monitoring can mainly be attributed to 
variances in calculating the intake from a unit bioassay measurement (1 Bq/day in 
urine) and not so much in calculating the CED from a unit intake (1 Bq/day 
intake).  Thus, it is clear that information regarding solubility class is specifically 
important for urine monitoring.  
 
Table 3.7:  CED for different solubility classes. 
Solubility class CED normalised (urine) a) CED normalised (lungs) a) 
F 0.0006 - 
M 0.010 0.48 
S 1.000 1.00 
a) Calculations were done with IMBA assuming: 
• chronic intake over 28 days for urine and 180 days for lung, 
• ICRP default values, 
• low enrichment (IMBA values: 3.5%), 
• 1 Bq/day measured in urine sample on day 30 and  
• 1 Bq measured in lungs on day 180. 
 
3.1.2.3 Factors to consider when evaluating solubility class 
Within a specific solubility class, there can also be a wide range of dissolution 
rates.  Most uranium compounds are actually a mixture of different chemical 
forms.  This can result in a compound having fractional characteristics of F, M 
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and S at the same time.  For UF4, the dissolution rate varies because of a 
significant fraction of the UF4 are Type F and S solubility classes and an 
appreciable fraction is Type M [EI94].  However, Type M is the recommended 
solubility class since the solubility of UF4 is not strongly dependant on process 
history [EI94].  To an extent, lower Type S fractions were found for UO3 which 
has the same recommendation as UF4 [EI94] and indeed UO3 may even display 
characteristics of Type F compound [RU01].  As such, the ICRP default solubility 
class for both UO3 and UF4 is Type M.   
 
Another factor that need to be taken into account comes from the reviews done by 
Eidson [EI04] and Rucker [RU01] where it was found that the solubility of 
uranium oxides is very dependent on heat treatment.  High temperature treatment 
involves temperatures that are close to or in excess of 800°C.  The solubility class 
is strongly dependant on the materials process history according to Ref. [AN99].  
Processing (thermal treatment) has an effect on the specific surface area of 
particles and subsequently the particle size distribution (AMAD) and also the 
dissolution.  Heat treatment decreases the specific surface area, making the 
particle less soluble, thus closer to Type M solubility [RU01].   
 
The rate of oxidation of uranium metals (UO2) may also affect the solubility.  
Studies from actual exposure intakes have shown that some of the compounds 
indicated different solubilities, especially for compounds with a default solubility 
of Type S [EI94].  In particular, U3O8 is highly sensitive to process history, but 
most are consistent with Type S solubility class.  Uranium oxides (e.g. U3O8, 
UO2) will rather behave like Type M, except in cases of long term oxidation.  
Uranium metal alloy (e.g. UAl3) is classified as Type S [RU01].  The ICRP 
default class for uranium oxides and metals are Type S.  As can be seen, the 
literature recommendation is that these default values should be used with caution.   
 
3.1.2.4 Recommendations regarding solubility class 
Incorrect solubility class can lead to significant under- or over-estimation of CED, 
as can be seen in Table 3.7.  Default values are usually on the conservative side, 
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resulting in the highest possible CED.  Following the principle of a “graded 
approach”, the resultant uncertainty in CED is acceptable for low doses.  But in 
instances where doses approach investigation levels, it is recommended that 
further information is gained regarding the solubility to ensure a best estimate of 
the dose.  This is especially so in the case of Type S compounds and preferably 
solubility studies should be performed to characterise the actual materials present 
at Necsa.  Excretion rates can also be used to determine the solubility class (see 
Section 3.3.1).  When setting up a monitoring programme or deciding on radiation 
protection control measures (e.g. ventilation, confinement, etc.) it is recommended 
to use the conservative default values, but the actual solubility class should be 
used for dose calculations if the doses approach investigation levels.   
 
Normally found in a uranium plant are the compounds UAl3, UO3, UO2(NO3)2, 
UF4, UO2 and U3O8.  The solubility classes of compounds at Necsa’s uranium 
plant, based on [RU01] and [EI94], can be classified as Type M, except where 
there is high temperature treatment of UO2 or long term oxidisation of uranium 
metal (UO2, U3O8).  Long term oxidation does not occur within the uranium plant, 
but high temperature treatment of UO2 does occur.  This process is in an enclosed 
glove box, thus minimising the possibility of intake.  Uranium metal (Type S) 
exposure could also occur during the reduction of UF4 to uranium metal and 
during the melting of uranium metal and production of uranium shavings.  But 
these either occur in a glove box or are done with the necessary respiratory 
protective equipment.  Some processes are done on an ad-hoc basis, enabling task 
monitoring (see Section 3.2.1 for description of exposure scenarios).  Thus, one 
can recommend a routine monitoring programme assuming exposure to Type M, 
while task monitoring for Type S is recommended (ad-hoc processes). 
 
3.1.3 Radiological characteristics 
Within a uranium recovery and fuel production facility, one only needs to 
consider uranium and its daughter products.  The radiological characteristics of 
uranium are described in Section 2.1.2.   
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3.1.3.1 General radiological characteristics 
The three major uranium isotopes mainly decay by emitting alpha and β- particles.  
Subsequently, dose conversion factors (DCF) for the different isotopes of uranium 
will be the same because of similar radiological characteristics.  Of concern is the 
high LET value for the alpha particles, thus posing a significant internal 
radiological hazard (see Section 2.1.8). The inhalation dose conversion factors for 
Type F, M and S are listed in Table 3.8. 
 




Type F Type M Type S 
234U 6.4 x 10-7 2.1 x 10-6 6.8 x 10-6 
235U 6.0 x 10-7 1.8 x 10-6 6.1 x 10-6 
238U 5.8 x 10-7 1.6 x 10-6 5.7 x 10-6 
 
The physical half-life of the isotopes is significantly longer than a typical 
monitoring period (see Table 2.1).  Thus, the physical half-life does not need to be 
considered when deciding on a monitoring frequency.  The biological half-life and 
subsequent effective half-life is important and is discussed in Section 3.3.3.  Due 
to the long half-lives, the uranium daughter nuclides do not build-up in the body 
and subsequently do not pose a significant radiological risk.  The internal dose 
contribution of the daughters is less than 10%.  For radionuclides that decay into 
stable progeny, or into progeny with radioactive half-lives very much longer than 
the human lifespan, only the radiation emitted by the parent radionuclide needs to 
be considered for dosimetry.  The IMBA software has various mathematical 
solutions to take this into consideration [BI94].   
 
As mentioned, the three major uranium isotopes decay mainly by emitting alpha 
and β- particles.  As such, uranium is monitored usually with in-vitro techniques 
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such as urine and faecal analysis.  Lung counting is also done, using the 186 keV 
photon emitted by 235U.  This is discussed further in Section 3.3.1. 
 
3.1.3.2 The effect of mass enrichment on committed effective dose 
Most of the mass of uranium consists of the isotopes 234U, 235U and 238U in 
various mass combinations depending on the enrichment process.  The mass 
distribution between the different isotopes for various enrichment grades for the 
Pelindaba enrichment process is listed in Table 3.9.  One should take note that the 
expression “enrichment grade”, indicates the mass enrichment of the 235U isotope 
since 235U is the fissionable isotope of importance during fuel production. 
 
Table 3.9: Uranium mass distribution shown as a percentage at different 
enrichment grades for the Pelindaba enrichment process. 
235U 234U 238U 
0.72% 0.0055% 99.275% 
1% 0.0062% 98.994% 
2% 0.0127% 97.990% 
5% 0.0318% 94.970% 
10% 0.0644% 89.940% 
20% 0.132% 79.870% 
30% 0.208% 69.790% 
40% 0.299% 59.700% 
50% 0.415% 49.590% 
60% 0.571% 39.430% 
70% 0.769% 29.230% 
80% 1.050% 18.950% 
93% 1.518% 5.482% 
 
The effect of enrichment on the CED for a unit intake is shown in Table 3.10.  As 
can be seen, enrichment has a minimal effect on the CED since the dose 
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conversion factors are almost the same for the different uranium isotopes (see also 
Table 3.8).  The 234U isotope is the largest contributor to the dose since most of 
the activity in the uranium is due to 234U.  This is discussed in the next section.   
 
Table 3.10: CED per enrichment normalised to 5% enrichment. 




a) Calculations were done with IMBA assuming: 
• Chronic intake over 28 days, 
• ICRP default values and  
• 1 Bq/day intake. 
 
The Specific Activity (SA), of the different uranium isotopes is listed in Table 2.1 
(page 11).  The SA for 234U is significantly larger than for the other isotopes.  The 
total activity in the uranium mix is thus mostly due to 234U; subsequently the CED 
will mostly depend on the 234U mass content in the mixture.  The activity 
contribution of 234U is significantly lower at enrichments less than 2%. 
 
The SA of a mixture is calculated from an assumed 235U Mass Enrichment (ME) 
distribution.  The SA of the compound (mixture) is the sum of the Weighted 
Specific Activity (WSA) for each nuclide.  The WSA is a specific nuclide’s 
contribution to the total activity of the mixture and is calculated as follows: 
 




WSAiU  = SAiU  × MEiU , (3.2) 
 
where  
SAcompound = specific activity of the mixture for a specific 235U ME 
SA  = specific activity for each nuclide 
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WSA  = weighted specific for each nuclide 
ME  = mass enrichment for each nuclide 
i  = uranium isotopes, 234U, 235U and 238U respectively. 
T 
he weighted specific activity for 234U, the % contribution of 234U to the total 
activity and the change in the SA for various enrichment grades can be seen in 
Table 3.11.  As expected, the SA changes significantly due to the change in 234U 
mass content in a given mixture.   
 
Table 3.11: Specific Activity of a mixture per enrichment. 
Mass enrichment: 
(235U mass contribution) 
234U WSA 
(Bq/g) 




0.72% 1.27 x 104 2.56 x 104 50% 
1% 1.43 x 104 2.74 x 104 52% 
2% 2.93 x 104 4.31 x 104 68% 
5% 7.35 x 104 8.92 x 104 82% 
10% 1.49 x 105 1.68 x 105 89% 
20% 3.05 x 105 3.31 x 105 92% 
30% 4.80 x 105 5.13 x 105 94% 
40% 6.91 x 105 7.30 x 105 95% 
60% 1.32 x 105 1.37 x 106 96% 
70% 1.78 x 105 1.84 x 106 97% 
80% 2.43 x 106 2.49 x 106 97% 
93% 3.51 x 105 3.58 x 106 98% 
 
3.1.3.3 Determination of 234U activity 
As can be seen above, the isotope of importance for internal dose is 234U.  Most 
monitoring techniques can only measure the 235U activity.  The total activity in a 
given uranium mix (and specifically the 234U activity) is usually derived from the 
measured 235U activity using specific activity and mass distribution [RU98].  This 
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implies that the mass distribution (enrichment) should be known during dose 
calculations.  The exact enrichment is usually not known since workers can be 
exposed to different enrichments during different plate productions or during the 
initial feed batch production when various different enrichments are blended 
together.  Errors in deriving the 234U activity and subsequent total activity can thus 
lead to significant errors in the CED [FI94].  The 234U isotope is the predominant 
contributor to SA of the uranium mixture and subsequently the predominant 
isotope for internal dosimetry [AN07].   
 
Assuming that a unit activity (1 Bq/day 235U for urine and for lungs a 1 Bq 235U) 
is measured then the resultant total activity of uranium in the measurement is 
shown in Fig. 3.5 and Table 3.12.  The total activity is directly proportional to the 
calculated CED.  As can be seen, the total activity decreases sharply for low 
enrichments where after it increases as the enrichment increases.  The total 
activity is calculated as follows: 
 
Total Activity  =  1 Bq U

 SA
 ME"  ×  SA$%&'%()* 
, (3.3) 
 
Workers at Necsa’s uranium plant can be exposed to a range of enriched uranium 
products (mostly between 5% and 50%).  The specific enrichments that are used 
are not mentioned here due to confidentiality reasons.  An uncertainty in 
enrichment can lead to significant under or over estimation of the total activity, as 
shown in Table 3.12.  It is recommended that for routine monitoring a default 
enrichment of 30% is assumed for all exposures.  This implies a maximum 
underestimation of 2% (0.98 at 10% ME) and maximum overestimation of 17% 
(1.17 at 50% ME).  For enrichments larger than 50% and less than 5% the under- 
and over-estimation is significantly larger.  Should it be that exposure is expected 
at these extremes, i.e. low enrichment (depleted or natural uranium) or high 
enrichment, it is recommended that the actual enrichment should be used.  Using 
the actual enrichment is also recommended if an unexpected intake has occurred 
or if the calculated CED exceeds a predetermined dose. 
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Figure 3.5: Total activity for different MEs per unit 235U measured. 
 
Table 3.12: Total activity for different MEs per unit 235U measured. 












a) Normalised to 30% enrichment. 
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3.1.3.4 Variances in mass enrichment 
Matters are further complicated since the mass contribution ratio between the 
different uranium isotopes could also differ from those stated in Table 3.9.  The 
values in Table 3.9 are specifically for the historic enrichment process used by 
Necsa.  Since the 234U activity is derived from the mass distribution, it adds 
further uncertainty and inaccuracy to the dose calculation.   A plant could produce 
various blends of uranium isotopes (due to up or down blending) that results in a 
product having a SA that could differ from the predicted calculations [AN07].  
The 235U/234U mass ratio is enrichment process specific and can differ 
significantly between enrichment processes [FE04].  Literature review indicates 
average mass ratios that differ from each other. Average mass ratios of 112 and 
105 are cited in Ref. [FE04].  The average for the Necsa enrichment process 
(between 5% and 50%) is 141, as can be seen Table 3.13.  This differs 
significantly from reported values.  In recent times Necsa purchased enriched 
uranium for which the mass ratios differ from those of Necsa.  Purchased uranium 
forms currently a small portion of the uranium being processed by Necsa, but this 
contribution can increase in the near future and a more representative mass 
distribution should be obtained.   
 
Table 3.13: 234U/235U mass ratio for different MEs. 









Standard Deviation 15 
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3.2 Exposure scenarios 
The exposure scenario provides information that will aid in determining the 
monitoring programme and in calculation of CED and can be characterised 
according to: 
• sources of intake (spatial), 
• routes of intake (pathway) and 
• time of intake (temporal). 
Each of the contributing factors to the exposure scenario is discussed in detail 
below together with discussion of the software modelling of these scenarios.  
 
3.2.1 Sources of intake (spatial) 
A range of uranium physical forms and compounds, with different physical and 
chemical properties and behaviour, are used and produced at Necsa’s uranium 
plant.  Plates are manufactured to be used as fuel plates for the research reactor or 
as target plates to be used for isotope production.  Scrap originating from various 
processes (reclamation of uranium waste) within the plant or U3O8 is used as 
feeding material to produce UF4 and subsequently uranium metal.  Uranium 
metals are cut into shavings in a glove box with negative pressure relative to the 
room.  The shavings are dissolved in a nitric acid solution to produce a uranyl 
nitrate solution (UO2(NO3)2).  The uranyl nitrate is further concentrated and 
purified in fume cupboards and glove boxes.  Ammonium di-urinate (ADU, 
UO3.H2O.NH3) is produced during an ammonia precipitation stage.   
 
At this stage all of the processes are wet chemical processes, except for uranium 
metal shavings.  The probability of airborne contamination is thus the highest 
during the metal shavings stage.  The ADU is placed in an oven for fluorination.  
The ovens are enclosed in a perspex box at a negative pressure relative to the 
room.  The ADU is converted to UO3 during heating and are then reduced to UO2.  
Hydrogen fluoride (HF) is added and UF4 is formed.  The UF4 is milled and 
magnesium oxide is added were after it is placed in an oven and heated to form 
UO2.  The UO2 and aluminium is either melted separately or together to form pure 
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uranium ingots or a uranium alloy (UAl3).  This is a well known process and the 
same processes are described by [RU01] and [EI94].   
 
Workplace surveillance has indicated that the areas surrounding the ovens are 
high airborne contamination areas and pose a high risk for intakes.  Exposure to 
workers is minimised and controlled primarily by engineered methods, i.e. 
containment (glove box), fume hoods and ventilation.  Additional respiratory 
protective equipment is prescribed in instances where containment is breached or 
procedures include working with furnaces (ovens).  Contamination control 
(housekeeping) is also strictly enforced.  Workers routinely work in all of the 
areas except for the uranium metal melting-area and the area where uranium metal 
scraps and shavings are produced.  Work in these areas is on an ad-hoc basis and 
is controlled by task monitoring.   
 
3.2.2 Routes of intake (pathway) 
The most frequent route of uranium intake for workers is by inhalation according 
to Refs. [FI94] and [DO04].  For routine monitoring it is assumed that the intake 
is only inhalation and none is ingested directly through the mouth.  Inhaled 
particles are deposited throughout the respiratory tract and a small fraction of 
those deposited is swallowed and excreted through the GI tract.  The ratio of 
excretion between urine and faeces as well as lung counts can be used as indicator 
of the solubility class of the uranium and as an indicator of the route of intake.  
This is discussed in Section 3.1.2 and Section 3.3.1.4.   
 
A portion of the uranium is ingested directly through the mouth during routine 
exposures and the assumption of only inhalation can lead to potential errors in the 
CED.  Ingestion can happen due to poor occupational hygiene, e.g. workers not 
washing their hands and subsequently contamination is ingested during smoking 
or eating and incidents have been found where a worker contaminated a writing 
pen and placed it into the mouth.   
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A study by Lee [LE10] found that the exposure pathway (see Section 2.2.2) plays 
an important role and has a significant effect on the CED for intakes of 241Am.  
For uranium intakes the effect is just as significant.  This is substantiated in Table 
3.14 indicating the variation in CED based on the fraction inhaled versus fraction 
ingested.   
 
Table 3.14: Normalised CED - inhalation versus ingestion, Type M and S. 
Route of Intake 
(inhalation : ingestion) 
CED normalised to only inhalation a) 
Type S Type M 
1:0 1.00 1.00 
3:1 0.75 0.76 
2:1 0.67 0.68 
1:1 0.50 0.53 
1:2 0.33 0.37 
1:3 0.25 0.29 
0:1 0.00 0.05 
a) Calculations were done with IMBA assuming: 
• chronic intake over 30 days, 
• ICRP default values, 
• low enrichment (IMBA values) and  
• 1 Bq/day measured in urine sample on day 30. 
 
As can be seen, the impact on CED is significant, but a significant fraction of 
ingestion is highly unlikely during routine exposures.  An increasing fraction of 
ingestion leads to lesser doses and as such an assumption of only inhalation will 
be a conservative (maximum) value and is acceptable for routine urine 
monitoring.  It is advisable to take ingestion into consideration if a predetermined 
investigation level (e.g. 1 mSv) has been exceeded, if ingestion is highly likely or 
suspected or if there was an incident (acute intake).   
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The route of intake should also be considered for routine monitoring that is based 
only on faecal analysis or lung counting [LE10].  An AMAD value different from 
the ICRP default value will affect the fraction ingested from the respiratory tract.  
This effect is less severe for urine monitoring (see Section 3.1.1).  Again, as such, 
the route of intake does not need to be considered for routine urine monitoring 
except in the cases mentioned above.  However, it should be noted that faecal 
analysis can also aid in the determination of the route of entry (see Section 3.3.1).  
 
3.2.3 Time of intake (temporal) 
Due to the routine nature of the work done in a uranium plant, where there is 
seldom ad-hoc tasks for the majority of the workers, one can assume that 
exposures will be distributed evenly over the monitoring period.  Workplace 
surveillance will indicate significant increases in airborne and surface 
contamination levels, thus indicating a possibility of an acute intake or an uneven 
distribution of airborne contamination of a monitoring period.  A review of 
workplace surveillance data has confirmed this.   
 
However, this is not true for maintenance workers who perform ad-hoc tasks and 
significant variances in airborne levels were found when containment had been 
breached.  During the majority of maintenance operations intakes are not expected 
since tasks are well controlled and the necessary radiological protection 
equipment is worn.  Maintenance workers are monitored routinely (monthly urine 
samples).  Experience has shown that unexpected intakes can usually be traced 
back to an ad-hoc tasks and time of intake could have a significant impact on the 
actual dose.  In some instances are pre- and post-task monitoring prescribed, 
consisting of lung counting and/or urine sampling which is time consuming and 
costly.  As an alternative, nose blows or nasal swabs are used as screening tests.  
Nose blows are less time consuming, cost less and give an instant indication of a 
very recent intake i.e. during the task (see Refs. [DO99] and [DO04]).   
 
Dose conversion factors for routine exposures are based on the assumption of an 
acute intake in the middle of the monitoring period [IC97].  Newer versions of 
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dose calculation software, such as IMBA, make it possible to simulate chronic 
exposures and have a more representative model of actual exposure scenarios.  
Previous software used by Necsa (LUDEP) was not capable of simulating chronic 
intakes [NR96].  Simulating chronic intakes rather than using the ICRP default of 
an acute intake is preferred and is thus consistent with the best estimate approach 
of IDEAS.  The CED for an acute intake versus a chronic intake is compared and 
the effect on the calculated CED is shown in Table 3.15.   
 
Table 3.15: Chronic versus acute normalised to chronic intake. 
Monitoring period 
(Days) 
Acute CED / Chronic CED a) 
Type M Type S 
12 1.05 1.06 
28 1.14 1.16 
58 1.28 1.30 
88 1.34 1.36 
a) Calculations were done with IMBA assuming: 
• acute intake on day 6, 14, 29 and day 44, 
• chronic intake over 12, 28, 58 and 88 days, 
• ICRP default values, 
• low enrichment (IMBA values) and  
• 1 Bq/day measured in urine sample on day 14, 30, 60 and 90. 
 
In all instances, the CED for an acute intake is larger than the CED for a chronic 
intake over the same period.  The difference increases as the length of the 
monitoring period increases and is significant for monitoring periods larger than a 
month (> 16%).  These values are consistent with what was found by Birchall 
[BI06].  Assuming a chronic intake is acute leads to an overestimation between 
5% to 40% depending on the monitoring period.  Newer versions of software for 
calculating CEDs are more capable of simulating exposure scenarios and thus it is 
recommended that the chronic option should be used for routine exposure 
calculations as suggested by Refs. [BI06] and [DO08].  Chronic intake can also be 
assumed for maintenance workers but should be used with caution.   
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3.2.4 Software modelling of exposure scenarios 
The latest commercial internal dose calculating software available enables 
simulating exposure scenarios much more representative of the actual scenario, 
especially simulating different routes of intake and various times of intake 
combinations.  Software for calculating CED was reviewed in Ref. [AN03].  
Criteria used were, amongst others, practical use of codes, graphical capabilities, 
parameters available for change, data fitting, choice of biokinetic models etc.  
Necsa recently purchased IMBA (Integrated Modules for Bioassay Analysis) 
which is developed by the NRPB of the United Kingdom.  IMBA was found in 
Ref. [AN03] to be a comprehensive code which uses the latest ICRP biokinetic 
and dosimetric modules.  A CED was calculated for two reference cases and 
results were found to be homogeneous and accurate.  The IMBA code is highly 
flexible and includes the modelling combination of intake pathways and various 
exposure scenarios.  It also allows for variability in several of the biokinetic and 
physiochemical parameters.  Using IMBA, by a relative expert user, will thus 
further ensure that results are the best estimate (harmonised and accurate) and 
proportional (graded approach). 
 
3.3 Individual monitoring 
Existing regulatory requirements are sometimes difficult to meet due to technical 
challenges related to speed, accuracy, detection limits, exposure scenario 
uncertainties and cost implications.  These are the challenges faced by the current 
bioassay techniques [SC03].  The features of different bioassay techniques and 
their limitations including monitoring frequency and technique sensitivity are 
each dealt with in turn below. 
 
3.3.1 Bioassay techniques 
A survey done under the auspices of the OMINEX project found different 
preferences for routine monitoring of uranium [RA03].  Subsequently, the 
OMINEX project investigated various bioassay monitoring programmes [NR04] 
and recommended the programme given in Table 3.16.  The programme 
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recommended by the DOE site at Hanford is given in Table 3.17 [CA09].  The 
various different techniques are detailed below. 
 
Table 3.16: OMINEX monitoring programme for uranium [NR04]. 
Compound Type F Type M Type S 
Monitoring Urine Urine and Faeces Lung and Faeces 
 








Type F: Chronic 
exposure 
Type F: Infrequent or 
acute exposure 









Biweekly or monthly 
urine samples 
Quarterly monitoring or 
post task monitoring for 
short duration work. 
Quarterly urine 




3.3.1.1 Urine analysis 
Urine monitoring is in most cases not interpreted quantitatively, but rather used as 
confirmation of satisfactory conditions [IC97].  This is also the case for Necsa and 
only intakes exceeding a prescribed action level are converted to a CED.  Necsa 
currently use a technique called Delayed Neutron Counting (DNC) for monthly 
analysis of uranium in urine for chronic exposures to Types M and S.  Quarterly 
confirmatory DNC analysis is done for infrequent and low exposures of Type M 
uranium.  DNC is a neutron activation analysis technique that determines the 235U 
activity based on delayed neutron activation after irradiation.  Delayed neutrons 
are produced during fission by thermal neutrons.  The number of delayed neutrons 
can be related back to the original 235U activity.  This technique is very sensitive 
(see Section 3.3.3) but requires an irradiation facility.  The samples are irradiated 
at the Necsa SAFARI-1 research reactor.  This implies turnaround times for 
results up to two weeks.   
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Type F uranium is monitored quarterly with fluorometry to ensure chemical 
toxicity levels are not exceeded.  Fluorometry is based upon the fluorescence of 
the uranium compound when exposed to ultraviolet light.  The intensity is 
proportional to the uranium concentration.  Fluorometry is significantly faster 
than DNC but its sensitivity is at least an order of 100 less sensitive, which is 
inadequate for monitoring of Type M and S uranium.  Exposed workers at the 
uranium plant are monitored monthly with DNC.  All samples are singe voids and 
24 hour samples are only given in instances of unexpected intakes.  
 
Literature study, Ref. [HU03] and [SC07], indicated that alpha spectrometry is the 
technique mostly used for the determination of alpha emitters in urine (such as 
uranium), but the main disadvantage is the long counting time required (up to 
several days).  Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) is not 
often used, but the technique has shown to be as sensitive as alpha spectrometry 
and modified newer ICP-MS techniques have even much lower sensitivities 
[OE07].  ICP-MS’s main advantage is its short analysis time (several minutes), 
but the equipment is expensive.  ICP-MS will be the preferred technique used in 
future according to Refs. [SC03] and [SC07].   
 
Another technique (other than DNC) with better sensitivity is not necessary for 
Type M monitoring, but better sensitivity is necessary for Type S monitoring (as 
will be seen in Section 3.3.3).  However, the required sensitivity levels for Type S 
are within the order of dietary intakes (see Section 3.3.2).  Thus, it problematic to 
distinguish between dietary intake and occupational intakes at levels close to the 
required sensitivity levels.  No immediate improvements thus are necessary for 
Necsa’s uranium urine programme, but techniques with faster turnaround time 
and lower sensitivity would be advantageous.  
 
3.3.1.2 Lung counting 
Lung counting at Necsa is done annually for all workers exposed to all forms of 
uranium.  The counting time is 30 minutes.  Longer counting times (60 minutes) 
are used during unexpected intakes.  The newly purchased Whole Body Lung 
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Counter (WBLC) from Canberra consists of 4 Broad Energy Germanium (BEGE) 
detectors for lung counting and a Sodium Iodide (NaI) detector for whole body 
scanning.  It is also housed (shielded) in a low background steel chamber thus 
decreasing background levels significantly, thereby improving signal to noise 
ratio and subsequently also the detection capability.  The previous counter set-up 
consisted of a single NaI(Tl) detector.  The new WBLC was also supplied with 
the latest analysis software (GENIE 2000TM and ABACOSTM) allowing efficient 
analysis of spectra and data.  The BEGE detectors provide better resolution than 
the NaI detector at lower energy ranges, particularly for the 235U 185 keV peak.  
Sensitivity has also improved from the previous set-up.   
 
Taking into consideration the improved sensitivity, lung counting on its own is 
still not adequate for routine uranium monitoring, due to poor sensitivity (see 
Section 3.3.3).  It is only complementary to urine monitoring and useful for 
detecting significant intakes, especially Type S.  Lung counting is an indication of 
accumulated exposures over longer periods (6 or 12 months), thus is useful to 
monitor for long term build-up, especially for highly insoluble compounds.  
Previous chronic (up to several months) intakes should thus be taken into account 
when evaluating lung counts.  Carbaugh [CA03] has recommended lung 
monitoring for plutonium and is equally true for uranium [FI94].  Urine analysis is 
less reliable for detecting significant Type S intakes and lung counting provides 
more reliable results [TA03].  This is due to the biokinetic behaviour of Type S 
uranium, staying longer in lungs.  Lung counting is more reliable but not 
necessary more sensitive as seen in Section 3.3.3.   
 
To improve the sensitivity, it is suggested summing lung counts over a group of 
individuals in cases where chronic exposure to Type S is expected [TA03].  It 
entails counting a group of individuals and the summing of all of the spectra.  This 
will lead to an improvement in the detection capability and an average CED can 
be calculated and allocated to each individual.  However, this is limited to a group 
of individuals who have had similar exposure scenarios and who were exposed to 
the same single uranium compound i.e. same physiochemical properties and 
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chronic exposure.  This type of exposure scenario is unlikely for a uranium plant 
at Necsa and would thus not be applicable for the present study.  But it can be 
used in unexpected intakes where more than one individual was involved. 
 
The current lung counting technique at Necsa is optimised and the best technology 
available is used. It compares well with sensitivities of other systems published 
and no improvements are thought to be necessary.  
 
3.3.1.3 Faecal analysis 
Faecal monitoring is invasive (inconvenient) and there are usually resistance 
against it from workers. Samples are also cumbersome to collect.  Alpha 
spectrometry is the preferred method for analysis of faeces and minimum detected 
activity of 1 mBq/day is achievable [HU03].  Faecal monitoring is also 
recommended for monitoring of Type S uranium due to its lower sensitivity.  A 
further advantage of faecal monitoring is its ability to aid in the differentiation 
between intakes of Type M and S (see later in this section), an indication of route 
of intake and can also be used as indication of the AMAD (see Section 3.1.1).   
 
Another advantage of faecal monitoring is in the determination of the route of 
intake [DO08].  Ingested and inhaled uranium will both deposit in the upper 
respiratory tract and will clear through the faeces within a few days.  Faecal 
results after 10 days will only be inhaled material.  These data can then be 
extrapolated to the first few days after intake and so indicate the inhalation 
component in the faecal results during that time.  Subsequently, the ingestion 
component of the faecal results for the first few days can be calculated.  Necsa is 
not yet capable of analysing faeces and it is currently under development.   
 
3.3.1.4 Technique combination 
As shown in Section 2.1.8, the chemical and physical form (physiochemical 
nature) of the uranium compound will determine its behaviour on intake and its 
subsequent biokinetic behaviour in the human body, which will determine the stay 
time within the human body and consequently the rate of excretion.  The 
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difference in biokinetic behaviour between respiratory tract (lungs) and 
gastrointestinal tract (faeces) and between kidneys (urine) and gastrointestinal 
tract (faeces) will result in different stay times and excretion rates. This can be 
used to differentiate between intakes of different solubility classes and intake 
pathways.  Uranium can be placed into three categories [EI94], the first being 
those compounds (Type F) that dissolve rapidly in the lungs and are thus excreted 
almost instantaneously in the urine with no retention in the lungs and 
subsequently very low excretion in the faeces.  The second category are 
compounds (Type M) with intermediate dissolution, such that both mechanical 
clearance via the gastrointestinal tract and dissolution are dominant with a certain 
retention in the lungs.  Subsequently, uranium will be detected in the lungs, urine 
and faeces.  The third category of compounds (Type S) dissolves slowly with 
significant retention in the lungs, resulting in predominantly mechanical clearance 
and subsequent high excretion in the faeces.  Thus, these techniques can provide 
valuable information for dose reconstruction.  The differences can be seen in Fig. 
3.6, Fig. 3.7 and Fig. 3.8.   
 
 
Figure 3.6: Difference in excretion rate of Type S uranium urine, faeces and 
lungs (taken from [IC97]). 
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Figure 3.7: Difference in excretion rate of Type M uranium in urine, faeces and 
lungs (taken from [IC97]). 
 
 
Figure 3.8: Difference in excretion rate of Type F uranium in urine and faeces 
(taken from [IC97]). 
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Type F uranium is highly soluble and it is almost instantaneously absorbed in the 
lungs and subsequently will not be detected.  After the first few days (> 10 days) 
of intake (Type M), the excretion in the urine and faeces will be almost similar 
where after (> 40 days) the excretion rate in the faeces will be less than in the 
urine.  This is in contrast to Type S uranium where the faeces excretion will 
always be more than the urine.  The ratio between the lung counts and urine 
results will also be significantly higher for Type S uranium, compared to Type M.  
It is not within the scope of the present study to calculate urine versus faeces 
versus lung ratios but is recommended that it be calculated and used for 
unexpected intakes.   
 
The above deliberation infers that the assessment of doses from intakes of 
uranium requires a combination of techniques in order to provide the best 
estimate.  Workers can be exposed to a mixture of uranium compounds with 
different routes of intake.  A combination of urine, lung and faecal analysis has 
shown to be the best methodology for assessing doses in such situations.   
 
3.3.1.5 Other 
Additional bioassay techniques such are hair and nail analysis are recommended 
[KA01] for better understanding and better estimation of exposures to uranium 
compounds.  This is due to the uncertainties associated with single void urine 
samples (see Section 3.3.2) and is recommended for special monitoring and not 
routine monitoring.  Hair and nails have the benefit of retaining the uranium for 
weeks or even months after an exposure and can also provide a time profile of the 
exposure.  As the hair grows it will keep record of the exposure at a specific time.   
 
Nasal swabs provide a quick and easy screening method to indicate unexpected 
intakes.  Nose blows or nasal swabs should be taken as a screening test (see Refs. 
[DO99] and [DO04]).  Nose blows are less time consuming, cost less and give an 
instant indication of a very recent intake (i.e. during the task).  Nasal swabs 
should be done immediately after the task but swabs may be negative if a worker 
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is predominately a mouth breather [MA06].  Nasal swabs may revert to 
background levels within 30 min to 60 min after intake. 
 
An individual monitoring programme, which includes personal air sampling and 
workplace air sampling, is recommended in order to ensure that intakes below the 
detection levels of the bioassay techniques (urine and lungs) are not missed.  It is 
specifically recommended for Type S exposures.  This type of monitoring is used 
to trigger additional bioassay monitoring in cases of abnormal levels of airborne 
contamination and also for dose calculations.   
 
3.3.2 Specific limitations and/or uncertainties for urine analysis 
Biokinetic models use urine excretion rates relative to a single day (24 hours).  
However, collection of such samples on a routine basis is often not convenient.  A 
24 hour sample implies that a person has to urinate in a collection bottle and this 
should be done for 24 hours (e.g. at work, at home, when they go shopping etc.).  
This can lead to missed voids or an incomplete 24 hour sample.  Collection of a 
single void sample is easy and compliance is generally high [KA01].  
Subsequently, most routine monitoring protocols use a single void which are 
normalised to a 24 hour sample.  The first section below discusses the two 
sampling methods and makes recommendation on when to use which method.  
The second section will describe the different normalisation techniques.  Dietary 
intake of uranium contributes to more uncertainty in the evaluation of urine and 
the effect thereof will also be discussed [MC99]. 
 
3.3.2.1 Singe void sample versus 24 hour sample 
A 24 hour sample on two or three consecutive days is recommended to avoid 
large uncertainties in the quantification of daily urinary excretion values [OE07].  
Excreted radionuclides may vary during the day and also varies from day to day 
due to variation in biological functioning of the human body.  The volume 
excreted per day is also highly individual, being age and gender dependant 
[OE07].  A single void is acceptable for routine monitoring, but it is thus 
 83 
recommended that 24 hour sample should be done in instances where more 
accurate and representative data are necessary.   
 
Currently, Necsa’s routine and task urine sampling programme consists of a single 
void sample.  Only during special monitoring (investigations) are 24 hour samples 
taken.  These samples are not necessarily taken in consecutive days.  This author 
recommends continuing with a single void sample for routine and task 
monitoring.  Continuous 24 hour sampling is also recommended for special 
monitoring, i.e. in instances where a predefined reference level has been exceeded 
or in case of an unexpected intake.  This could be if a screening test such as a 
nasal swab indicates an unexpected intake or if workplace monitoring indicates 
abnormal levels of airborne contamination.  A 24 hour sample should be taken for 
three consecutive days every week.  This should be done until enough information 
is available for dose calculation or until excreted levels have declined below the 
detection limits.  The above recommendations are in line with a “Graded 
Approach” where the effort (for gathering enough and accurate data) should 
commensurate with the risk.   
 
Another option besides true 24 hour sampling is a simulated 24 hour sample.  
Simulated 24 hour sampling consists of collecting samples just before retiring at 
night and all samples until and including the first void after rising in the morning 
on two successive days [MC99].  This will approximate the total volume for 24 
hour sampling.  To ensure consistency and not to add any uncertainty regarding 
methodology, the author recommends using just one method for 24 hour 
collection, i.e. true 24 hour sampling.  
 
3.3.2.2 Daily excretion rate normalisation 
As mentioned before, routine urine samples are a single void sample.  The activity 
concentration within this single void sample needs to be converted to total activity 
excreted per day in order to determine the CED.  Normalisation includes use of a 
reference man excretion rates, creatinine content in the urine or specific gravity.  
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Necsa uses 1500 mℓ/day as the standard daily urinary excretion volume, 





day ) = activity concentration +
Bq
mℓ.  × 1.5 +
mℓ
Day
. . (3.4) 
 
ICRP recommends a conversion factor of 1600 mℓ/day for an adult male and 1200 
mℓ/day for an adult female [IC02].  Oeh et al. [OE07] have found mean daily 
urinary excretion values of 1684 ± 719 mℓ/day for males and 1682  ± 823 mℓ/day 
for females.  The value for males compares well with ICRP recommended values, 
but differs significantly for females.  Other literature could not be found to 
confirm these values.  This confirms the high variability in excretion rates and it 
supports the recommendation in the previous section for 24 hour sampling.  A 24 
hour sampling protocol will negate the need for normalisation. The relative 
deviation from the ICRP values (shown in brackets) is given in Table 3.18. 
 





Oeh et al. [OE07] 
Male:  1600 1500 (0.94) 1684 (1.05) 
Female: 1200 1500 (1.25) 1682 (1.40) 
 
The effect of the Necsa’s values (see Table 3.18) is a 25% (1.25) overestimation 
in the calculated daily excretion for females and a 6% (0.94) underestimation for 
males with subsequently the same effect on the CEDs.   
 
The current 1500 mℓ /day is still recommended for routine CED calculations 
below the predetermined reference level.  This will simplify calculations for 
routine exposures and the underestimation for males and over estimation for 
females is still within acceptable criteria (see Section 2.3.3) and also provide a 
more accurate estimation of CED for higher doses.  It is this author’s 
recommendation to rather use the recommended conversion factors from ICRP in 
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the case where a predetermined reference level is exceeded or for unexpected 
intakes.  It will thus ensure that Necsa’s approach is “Harmonised and Accurate” 
and in line with the “Graded Approach” principle.   
 
Normalisation to creatinine levels which are much more stable between sexes, 
ages etc is should also be considered [MC99].  Discussion with Necsa’s 
radioanalytical laboratory pointed to some disadvantages of creatinine 
normalisation.  Determining creatinine levels involves analysis by off-site 
laboratories and as such is cumbersome and expensive.  Specific gravity analysis 
could be done by Necsa’s analytical laboratories and this needs further study and 
investigation.   
 
3.3.2.3 Dietary intake of uranium 
Dietary intake of uranium contributes to more uncertainty in the evaluation of 
urine samples and the reliance on single void samples [MC99].  There could be 
significant levels of uranium in urine due to dietary intakes.  Several studies have 
been done leading to significant variation in excretion rates which is dependent on 
intake foodstuffs and drinking water [MU07].  It should also be noted that these 
values can vary significantly between individuals and geographical locations.  
ICRP states values between 0.02 µg and 0.5 µgU/day.  This is consistent with 
studies done at the DOE’s Hanford site [MA06].  Average levels of 0.2 µgU/day 
and levels up to 0.6 µgU/day were reported.  It is recommended that Necsa should 
not correct for dietary intake, i.e. subtract it from urine results but rather 
determine a dietary intake range for Necsa workers and take it into consideration 
during intake evaluations.  It is recommended that urine values, below dietary 
level, are recorded, but not interpreted quantitatively.   
 
3.3.3 Monitoring frequency and sensitivity 
The two factors to consider are the recommended maximum underestimation and 
the maximum missed dose set by the ICRP (see Section 2.3.3).  The ICRP [IC97] 
limits the underestimation of the calculated CED to a factor 3, compared to the 
default assumption of an intake in the middle of the monitoring period.  By using 
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Eq. (2.11) the required sensitivity (decision level, LC) can be calculated as based 
on the missed dose.  This is shown in Table 3.19. 
 











3.3.3.1 Urine analysis 
Delayed Neutron Counting (DNC) is currently used by Necsa to determine 
uranium concentration in urine.  The detection capability (MDA) is 0.72 ng 
235U/ℓ.  The MDA as total uranium mass and as total uranium activity is 
calculated as follows: 
 
Y (ng U/l) = X (ng  U/l) /  ME235U , (3.5) 
 
where  
Y = MDA (total uranium mass) 
X = 235U MDA 
 ME235U  = mass enrichment for the 235U nuclide. 
 
Z (Bq U/l)   = Y (ng U/l) x SAcompound (3.6) 
 
where  
Z = MDA (total uranium activity) 
SAcompound = specific activity of the mixture for the specific 235U ME. 
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Substituting the specific activity of 5.1 x 105 Bq/g (ME = 30%, see Table 3.11), it 
equates to an MDA of 1.2 mBq/ℓ (100 ng total U/ℓ).  Using the reference male 
excretion rate of 1.6 ℓ/day (Table 3.18), it is equal to 2 mBq/day.  Mass 
enrichment of 30% was assumed as representative default enrichment (see Section 
3.1.3.4).  The MDA at different enrichments are also calculated and shown below.  
The MDA (stated as total activity) first decreases as the enrichment increases, but 
increase later on with increasing enrichment.  This is due to the conversion from a 
235U mass to total activity (see section 3.1.3.3 and Table 3.12).   
 
Table 3.20: MDA for urine analysis by DNC at different mass enrichments. 
Mass enrichment: 
(235U mass contribution) 
MDA 





0.20% 360.0 5.3 9 
0.50% 144.0 2.8 5 
0.72% 100.0 2.6 4 
1% 72.0 2.0 3 
2% 36.0 1.6 2 
5% 14.4 1.3 2 
10% 7.2 1.2 2 
20% 3.6 1.2 2 
30% 2.4 1.2 2 
40% 1.8 1.3 2 
50% 1.4 1.4 2 
60% 1.2 1.6 3 
70% 1.0 1.9 3 
80% 0.9 2.2 4 
93% 0.774 2.8 4 
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The detection capabilities of ICP-MS are typically 1-10 ng U/ℓ [OE07], [SC07].  
However, the detection capabilities can be bettered significantly (≈ 30 pg 235U/ℓ) 
with new improved ICP-MS methods.  For alpha spectrometry, detection values 
are in the order of 1 - 2 mBq [SC07].  The MDA of 2.4 ng U/ℓ (~ 2 mBq/ℓ) for 
the DNC technique compares well with values from other techniques.  It was 
unclear from the literature whether Decision Level or MDA where quoted by Oeh 
et al. [OE07] and Schmitzer et al. [SC07].  The author assumed it to be MDA.  It 
should be noted that the 2 mBq/ℓ MDA of the DNC technique is also in the same 
order as the 3.7 mBq/ℓ required in performance standards set by the American 
National Standard Institute (ANSI) [AN96].  The MDA (stated as CED) of the 
Necsa’s DNC technique for different solubility classes and monitoring periods are 
given in Table 3.21. 
 





MDA (Type M) a) 
(mSv) 
MDA (Type S) a) 
(mSv) 
30 0.08 0.009 1.0 
90 0.25 0.015 1.7 
a) Calculations were done with IMBA assuming: 
• chronic intake over 28 and 88 days, respectively, 
• ICRP default values, 
• ME = 235U (30%), 
• MDA = 2 mBq total uranium per day and measured in urine sample on day 30 and 90. 
 
For Type M uranium, the MDA is well below the LC goals set in Table 3.19.  It is 
also recommended to keep to a monitoring period of 30 days where exposure 
scenarios indicate a high possibility of intake.  This will enable better gathering of 
information in case of an unexpected intake.  However, for Type S, the MDAs are 
significantly higher than the LC goals.  Indeed, LC values are roughly half of the 
MDA values (see Eq. (2.10)).  Thus, the LC for Type S will not meet the set LC 
goals.  As indicated in Section 3.2.1, chronic exposure to Type S uranium is 
unlikely.  A routine monitoring programme is thus not necessary, but special and 
task monitoring is required for Type S exposures.  Other urine analysis techniques 
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as indicated above with better sensitivities can also be investigated.  The 
differentiation in excretion rates (biokinetic behaviour) between urine and faeces 
can be used to differentiate between intakes of different solubility classes.  Thus, 
although urine analysis (Type S) does not have the required sensitivity, it will 
provide valuable information for dose reconstruction.   
 
Assuming a worst case scenario where an acute intake occurred on the first day of 
a monitoring period, the underestimation for various monitoring periods for 
chronic intake is indicated in Table 3.22.  For Type M and S, the underestimation 
complies with the ICRP recommended underestimation of not more than a factor 
of 3 (0.33) for both monitoring periods.  It is thus recommended that no change is 
made in the monitoring periods of 90 and 30 days.   
 







30 0.58 0.57 
90 0.47 0.53 
a) Calculations were done with IMBA assuming: 
• chronic intake (over 28 and 88 days, respectively) versus acute intake on first day, 
• measurement done on day 30 and 90 respectively 
• ICRP default values and 
• ME = IMBA low enrichment option (3.5%). 
 
3.3.3.2 Lung counting 
Lung counts are reported by the analysis software if it exceeds the critical level.  
The critical level is equivalent to the decision level (LC).  An MDA value is also 
calculated by the analysis software and is given in Table 3.23.  The MDA is based 
on Eq. (2.10), corrected for counting time and attenuation by the chest wall.  The 
MDA values are for 235U activity and for counting times of 30 min and 60 min 
respectively.  These MDAs are similar to values (LLD = 3 Bq) found in the 
literature [LO05] and is less than the 7.4 Bq MDA recommended by ANSI 
 90 
[AN96].  A survey done by the EURADOS project reported MDA values of 3 - 5 
Bq [LO07].  The corresponding CED values are given in Table 3.24. 
 














MDA (Type M) a) 
(mSv) 
MDA (Type S) a) 
(mSv) 
180 (30 min) 0.5 9.3 19.0 
180 (60 min) 0.5 5.4 10.9 
365 (30 min) 1.0 14.7 22.2 
365 (60 min) 1.0 8.4 12.8 
a) Calculations were done with IMBA assuming: 
• chronic intake over 180 and 365 days,  
• counting times 30 min and 60 min,  
• MDA of 4.5 Bq and 2.6 Bq 235U (30 min and 60 min, respectively), 
• ICRP default values, 
• ME = 235U (50%) and 
• measured in lungs on day 180 and day 365. 
 
The CED values are significantly higher than the ICRP required LC goals set in 
Table 3.19.  A rule of thumb is that the LC value is approximately half of the 
MDA value.  As such, lung monitoring cannot on its own be used for routine 
monitoring for Type M and S uranium.  It is complimentary to urine monitoring 
as described in Section 3.3.1.2.  Increasing the monitoring period to 30 days 
resulted in a calculated measured MDA of ± 1.5 mSv for Type M which is still not 
in the same order as for urine monitoring.  Such low levels required count times of 
at least 1 hour which is also impractical for monitoring large number of people.   
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A monitoring frequency of 6 months (180 days) and a count time of 30 min are 
recommended for routine Type M monitoring (LC = 4.3 mSv).  This is to confirm 
that annual CEDs are less than intervention levels which are typically set at 6 mSv 
to 8 mSv annual CED.  Routine monitoring of Type S with only lung counting is 
impractical, but can still be used as an indicator of significant intakes (see Section 
3.3.1.2).  Improved detection capability can be attained by summing a number of 
spectra acquired over several consecutive days [TA03].  This is recommended in 
cases of unexpected intakes of Type S uranium.  The differences in biokinetic 
behaviour between the retention in the lungs and excretion in the faeces can be 
used to differentiate between intakes of different solubility classes.  Thus, 
although lung counting does not have the required sensitivity, it will provide 
valuable information for dose reconstruction.   
 







90 0.64 0.78 
180 0.47 0.76 
365 0.25 0.76 
a) Calculations were done with IMBA assuming: 
• chronic intake (180 and 365 days) versus acute intake on first day, 
• Measurement done on day 180 and 365, 
• ICRP default values and 
• ME = IMBA low enrichment option. 
 
Assuming a worst case scenario where an acute intake occurred on the first day of 
a monitoring period, the underestimation for various monitoring periods assuming 
the intake was chronic is given in Table 3.25.  For Type S, the underestimation is 
well within compliance of the ICRP recommended factor 3 (0.33) for all three 
monitoring periods.  For Type M, the underestimation is acceptable for the 90 and 
180 day monitoring periods, but below the criteria for the 1 year monitoring 
period.   Since mostly exposure to Type M is expected, it is thus recommended to 
change the monitoring period from 365 days to 180 days.  Lung counting is 
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complimentary to urine monitoring and a monitoring period of 90 days would not 
add significant value.   
 
3.3.3.3 Faecal analysis 
The detection capability for faecal monitoring is substantially lower than lung 
counting and urine analysis and is able to confirm Type S uranium exposures 
several days after intake.  MDA levels of 1 mBq/day by means of alpha 
spectrometry are possible [HU03] and translates to a CED of 1 µSv for an acute 
intake 7 days prior (Type S uranium enriched to 50%).   
 
3.3.4 Suitably qualified and experienced dosimetrist 
Intercomparison studies have shown that discrepancies between results can be 
attributed amongst other factors to the level of expertise of the dosimetrist.  Doses 
estimated shall be done by suitable qualified individuals using a person-specific 
approach.  Due to assumptions made, dose estimated independently by two 
persons can lead to variations up to a factor of 3.  This was not dealt with in the 
present study, but is an important factor.  The USA Department of Energy 
recommends the following [DO07a]: 
 
“The analysis of workplace and radiobioassay measurement data and the 
evaluation of internal dose involve complex evaluation and professional 
judgment. Personnel with responsibility for internal dose evaluation should have 
the necessary expertise and skill, based on appropriate education and training in 
conjunction with practical experience, to perform their assigned duties.”  “It is 
important that internal dosimetry specialists be capable of recognizing conditions 
warranting follow-up radiobioassay and dose evaluation. Personnel should be 
familiar with the relevant internal dosimetry literature and the recommendations 
of national and international scientific organizations with regard to internal dose 
evaluation.” 
 
The author thus recommends that a review and audit by another qualified 
individual is performed if the calculated dose exceeds a specific level.  During the 
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review, the assumptions and models used to derive the radiation dose must be 
evaluated, with mathematical derivations and the associated uncertainty.  This is 
in line with the requirements from project IDEAS. 
 
3.4 Monitoring strategy and protocol 
In summary, the following monitoring strategy and protocol is recommended for 
uranium monitoring at the uranium plan at Necsa.  This is based on 
abovementioned analysis and literature research.  Factors such as particle size, 
solubility, route of intake, time of intake, the required sensitivity and available 
bioassay techniques have been considered.  In essence, only routine monitoring 
for Type M uranium needs to be considered.  Due to the ad-hoc nature of Type S 
exposures, only task related monitoring is necessary.  This is also possible since 
exposures to Type S uranium are unlikely due to administrative and engineering 
controls applicable where Type S uranium is processed.  Therefore, based on a 
graded approach, the following monitoring programmes are recommended and 
detailed below. 
 
3.4.1 Monitoring protocol (IDMP) for Type M uranium intakes 
Monitoring for Type M uranium should be based on routine urine sampling. 
Complimentary to the urine monitoring, lung counting should also be done as 
confirmation of no significant intakes.  However, faecal sampling is not 
recommended on a routine basis, but should be done in the instance of unexpected 
intakes.  This recommendation is summarised in Table 3.26. 
 
Table 3.26: Recommended monitoring programme for Type M uranium. 
Bioassay Analysis technique Monitoring period 
Urine analysis DNC (Single void) Monthly 
Lung counting Gamma spectroscopy  180 days, (30 min count time) 




Based on a graded approach, the following different levels of CED calculation are 
recommended:  
 
Level 0: Annual projected CED < 1 mSv or less than dietary level 
• Record only urine analysis results. 
• CED need not be calculated. 
 
Level 1: Annual projected CED between 1 – 3 mSv 
• Uncomplicated CED calculation based on ICRP default parameters 
for solubility, AMAD and chronic intake.  
• Assume daily urine excretion rate of 1500 mℓ/day 
• No additional bioassay monitoring needed. 
 
Level 2: Annual projected CED between 3 – 6 mSv 
• Perform additional bioassay monitoring including 60 min lung 
count and additional single-void urine analysis. The lung count is 
to confirm that the CED does not exceed 6 mSv and the additional 
urine analysis will confirm a positive intake.   
• Perform realistic dose calculation.  Typical parameters to be 
adjusted relates to the material (AMAD, solubility and enrichment) 
and exposure scenario (time of intake). 
• Peer review of dose calculations. 
 
Level 3: Annual projected CED > 6 mSv  
• Comprehensive set of measurement data is needed, which includes 
24 hour urine sampling protocol, 60 min lung counting and faecal 
analysis.  The estimation of the CED will be based on the 
comprehensive set of measurement data from all of the available 
bioassay techniques.  The 24 hour sampling will ensure 
normalisation to individual specific excretion rate.  Lung and faecal 
results can also be used to assist in determining route of intake, 
solubility and AMAD.  Typically, parameters to be adjusted relate 
 95 
to the material (AMAD, solubility and enrichment), the exposure 
scenario (time and route of intake) and the individual (e.g. HRTM 
particle transport rates in case of inhalation).  Systematically 
change default model parameters until the fit is acceptable to all of 
the data and provide valid justification for rejected data 
• Consider alpha spectroscopy of urine in order to determine 
enrichment. 
• Peer review of dose calculations. 
• Evaluate results from previous monitoring periods and consider 
correcting for intakes during dose calculations. The reconstruction 
of an intake is usually performed on a basis of a single data point in 
a time series of measurements.  If more than 10% of the actual 
measured quantity can be attributed to intakes in previous 
monitoring intervals, making a corresponding correction is 
recommended. 
• Review the working conditions and circumstances of the exposure. 
 
The annual projected dose is accumulated over a period of 12 months assuming 
similar intakes in each monitoring period (MPe) and is given by  
 
Annual projected CED = Measured dose x Number of MPe per year. (3.7) 
 
3.4.2 Monitoring protocol (IDMP) for Type S uranium intakes 
Section 3.3.3 indicates that the sensitivities of current urine analysis and lung 
counting are inadequate to detect the slow absorbing Type S uranium to a 
satisfactory level.  The detection capabilities can be reduced significantly (≈ 30 pg 
235U/ℓ) with new improved ICP-MS methods.  This is well within the required 
sensitivity level.  Routine monitoring for Type S uranium is not essential when 
based on the current exposure scenario (see Section 3.2.1), but improved 
techniques capable (including faecal analysis) of detecting small Type S intake is 
recommended.   
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CHAPTER 4  
CONCLUSIONS 
 
The primary objective of the present study was to benchmark Necsa’ Internal 
Dosimetry and Monitoring programme (IDMP) for uranium against best 
international practices.  This was done with an extensive literature survey, 
addressing most of the pertinent issues in an IDMP.  A knowledge base was built 
up containing best practices and these practices were presented in the present 
study.  The literature survey entailed studying and understanding exposure 
scenarios within a uranium plant, and specifically the physiochemical nature of 
the uranium compounds found in a uranium plant.  A uranium monitoring 
programme, i.e. monitoring techniques and its capabilities, as recommend in 
literature, was described.  Shortcomings of Necsa’s programme were highlighted.  
The important parameters used during dose calculations and the effect it has on 
the calculated Committed Effective Dose (CED) were investigated.  Specifically, 
the present study included calculations of and validation of limits of detection and 
performance criteria for the various monitoring techniques used by Necsa. 
 
The objective of an IDMP is to obtain intake data and to assess the committed 
effective dose in order to contribute to the control of operations.  This aim was 
achieved firstly by the optimization of the monitoring programme (based on 
workplace exposure and physiochemical characterisation) in order to ensure that 
monitoring results are representative of the real exposure.  The second step is the 
optimising the evaluation of monitoring data (individual dosimetry) to ensure it is 
the best estimate (harmonised and accurate following a graded approach).  Each of 
the contributing factors for an effective IDMP is summarised below highlighting 
the impact of the factor, its effect on Necsa’s IDMP and recommendations. 
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4.1 Contributing factors to a internal dosimetry and 
monitoring programme 
Activity Median Aerodynamic Diameter (AMAD) 
CED calculations have shown a significant dependence on the AMAD value.  
Literature survey has shown that AMAD for a typical uranium plant such as 
Necsa are mostly between 4 µm and < 8 µm with a limited effect on CED (within 
± 5%).  Following a graded approach, the default ICRP AMAD value (5 µm ) will 
be acceptable for routine Type M monitoring (lung counting and urine analysis).  
The recommended default ICRP value are representative of the inhaled aerosol 
and do not significantly under- or over-estimate dose for AMAD values within the 
range found at Necsa.  However, more accurate AMAD values should be used for 
intakes close to or exceeding reference levels (in the case of lung counting). 
 
Solubility 
CED calculations indicated significant dependence on solubility.  The solubility 
classes of compounds at Necsa’s uranium plant can be classified as Type M, 
except in limited steps in the production process where it is classified as Type S 
uranium.  However, these either occur in a glove box or are done with the 
necessary respiratory protective equipment.  Literature confirmed ICRP 
recommended solubility classes but cautioned there could be large deviation from 
recommended default values especially during high temperate operations.  High 
temperature treatment of UO2 does occur, but the process is in an enclosed glove 
box, thus minimising the possibility of intake.  Thus, one can recommend a 
routine monitoring programme assuming exposure to Type M.  However, more 




CED calculations are not dependent on the enrichment since dose conversion 
factors of the three main isotopes of uranium are very similar.  However, 
determination of the total uranium activity from a measured value is strongly 
dependant on enrichment.  The total activity (specifically 234U activity) is derived 
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from the measure 235U activity.  A default 30% mass enrichment is recommended 
based on the exposure scenarios at Necsa (between 5% and 50%).  This will result 
in a limited effect on the resultant total activity and CED calculations (- 2% to + 
17%).  The 235/234U mass ratio is main factor determining the total activity.  This 
ratio is enrichment process specific and can differ significantly between 
enrichment processes.  Purchased uranium compounds could in future form a 
significant part of the uranium mix at Necsa and a different 235/234U mass ratio 
could have a significant impact on the CED calculations.  Thus, one can 
recommend a routine monitoring programme assuming a mass enrichment of 
30%.  However, more representative enrichment values should be used for intakes 
close to or exceeding reference levels.  It should be noted that Necsa has 
embarked on a programme to use low enriched uranium target plates for the 
production of medical isotopes.  This could also significantly impact the 
assumptions regarding enrichment. 
 
Route of intake 
Literature survey recommended inhalation as the most probable rout of intake.  
However, even a small fraction of ingestion can have a significant impact on the 
CED, leading to large overestimations.  Thus, it is recommended that the 
distribution between inhalation and ingestion should be investigated for intakes 
close to or exceeding reference levels.  A combination of bioassay techniques can 
be used to assist in the determination of the different intake fractions.   
 
Time of intake 
Literature survey has indicated that most exposures are chronic and not acute.  
Newer versions of software for calculating CEDs are more capable of simulating 
exposure scenarios and thus are recommended that chronic option should be used 
for routine exposure calculations. 
 
Urine analysis 
Another technique (other than DNC) with better sensitivity is not necessary for 
Type M monitoring, but better sensitivity is necessary for Type S monitoring.  It 
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should be noted that the required sensitivity levels for Type S are within the order 
of dietary intakes and the evaluation of low intake values should take dietary 
intake into consideration.  It is recommended that Necsa should not correct for 
dietary intake, i.e. subtract it from urine results but rather determine a dietary 
intake range for Necsa workers and take it into consideration during intake 
evaluations.   
 
The current DNC technique was found to be adequate and no immediate 
improvements thus are necessary.  However, techniques with a faster turnaround 
time and lower sensitivity would be advantageous. 
 
A singe void sample is recommended for routine urine monitoring.  It is 
recommended that Necsa continue with normalisation of the singe void sample 
using 1500 mℓ/day.  ICRP default excretion values or a 24 hour sampling protocol 
for intakes close to or exceeding reference levels are recommended.  
 
Lung Counting 
Lung counting on its own is not adequate for routine uranium monitoring, due to 
poor sensitivity.  It is only complementary to urine monitoring and useful for 
detecting significant intakes, especially Type S.  Lung counting is an indication of 
accumulated exposures over longer periods (6 or 12 months), thus is useful to 
monitor for long term build-up, especially for highly insoluble compounds.  The 
current lung counting technique at Necsa is optimised and the best technology 
available is used.  Although, sensitivities are not within the required levels, it still 
compares well with sensitivities of other systems published and no improvements 
are thought to be necessary.  It is also recommended that the monitoring 
frequency for routine monitoring be changed from one year to six monthly.   
 
Faecal analysis and technique combination 
Faecal analysis is currently not part of the routine monitoring programme.  The 
technique is not yet available at Necsa.  Faecal analysis has better sensitivity than 
urine monitoring for exposures to Type S uranium.  The difference in biokinetic 
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behaviour between respiratory tract (lungs) and gastrointestinal tract (faeces) and 
between kidneys (urine) and gastrointestinal tract (faeces) will result in different 
stay times and excretion rates. This can be used to differentiate between intakes of 
different solubility classes, AMAD and intake pathways.  The assessment of doses 
from intakes of uranium requires a combination of techniques in order to provide 
the best estimate.  Although faecal analysis is an invasive technique, it is 
recommended that Necsa implement this technique.   
 
4.2 Summary 
It was found that Necsa’s bioassay techniques for uranium are adequate and 
compares very well with international best practices.  DNC analysis of urine is 
adequate (acceptable sensitivity) for Type M uranium, however, turnaround time 
is still problematic.  A more sensitive technique (specifically for Type S uranium) 
with a better turnaround time will be beneficial and is recommended.  Urine 
analysis techniques with lower sensitivity would be an advantage for Type S 
monitoring but at such low levels it will be difficult to distinguish from dietary 
intakes.  Faecal analysis has a much improved sensitivity and could also assist in 
entry route determination.  The implementation of faecal monitoring is 
recommended.  No immediate improvements are thus necessary for Necsa’s 
uranium urine programme, but techniques with faster turnaround time and lower 
sensitivity would be advantages.   
 
The current lung counting technique at Necsa is optimised and the best available 
technology is used. The sensitivity of the Necsa’s lung counter compares well 
other published sensitivities and no improvements are necessary.  Since exposure 
to Type M is mostly expected, it is thus recommended that the monitoring period 
be changed from 365 days to 180 days based. This is to ensure the 
underestimation is less than a factor 3 as recommended by ICRP.  Lung counting 
is complementary to urine analysis.  As such, good sensitivity is not essential, 
however detection capability can be improved with increasing the counting time 
from 30 min to 60 min.  This is not recommended for routine counting, but only in 
cases of unexpected intakes.   
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Due to high variability in dose calculations, the aim is to have a consistent 
approach in determining the best estimate of the dose.  Thus, two independent 
evaluations should get the same result and the result should be as close as possible 
to the true dose.  Analysis done to quantify the effect of differences in 
physiochemical characteristic of the uranium compound (e.g. AMAD) and 
differences in human metabolic parameters (e.g. daily urine volume) has brought 
an understanding on how these parameters can influence CED calculation.  
Literature study and calculations support the defaults assumption to be used 
during CED calculations.  The dose calculation steps as described in Section 3.4.1 
ensures that Necsa’s methodology is aligned (harmonised) with international 
recommendation.  When using the appropriate parameters (depending on the 
estimated dose) and the recommended bioassay protocol, one is ensured that the 
calculated CED is also the best estimate (accurate).  Using IMBA, by a relative 
expert user, will further ensure that results are the best estimate (harmonised and 
accurate). 
 
It was shown that Necsa’s IDMP is in line with best international practices and 
adequate to demonstrate that exposures are optimised and below regulatory limits. 
The IDMP is adequate and able to demonstrate compliance with the performance 
criteria for monitoring and dose calculation.  Knowledge gained from the present 
study will further enhance the programme and assist in developing the necessary 
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